<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10385070</article-id><article-id pub-id-type="pmcid-ver">PMC10385070.1</article-id><article-id pub-id-type="pmcaid">10385070</article-id><article-id pub-id-type="pmcaiid">10385070</article-id><article-id pub-id-type="pmid">37514037</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics15071850</article-id><article-id pub-id-type="publisher-id">pharmaceutics-15-01850</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Practical Considerations for Next-Generation Adjuvant Development and Translation</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5677-8733</contrib-id><name name-style="western"><surname>Lykins</surname><given-names initials="WR">William R.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fox</surname><given-names initials="CB">Christopher B.</given-names></name><xref rid="c1-pharmaceutics-15-01850" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names initials="DT">Derek T.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Lodaya</surname><given-names initials="RN">Rushit N.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-15-01850">Access to Advanced Health Institute, Seattle, WA 98102, USA</aff><author-notes><corresp id="c1-pharmaceutics-15-01850"><label>*</label>Correspondence: <email>christopher.fox@aahi.org</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><volume>15</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">441865</issue-id><elocation-id>1850</elocation-id><history><date date-type="received"><day>01</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>21</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-22 19:25:31.557"><day>22</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-15-01850.pdf"/><abstract><p>Over the last several years, there has been increased interest from academia and the pharmaceutical/biotech industry in the development of vaccine adjuvants for new and emerging vaccine modalities. Despite this, vaccine adjuvant development still has some of the longest timelines in the pharmaceutical space, from discovery to clinical approval. The reasons for this are manyfold and range from complexities in translation from animal to human models, concerns about safety or reactogenicity, to challenges in sourcing the necessary raw materials at scale. In this review, we will describe the current state of the art for many adjuvant technologies and how they should be approached or applied in the development of new vaccine products. We postulate that there are many factors to be considered and tools to be applied earlier on in the vaccine development pipeline to improve the likelihood of clinical success. These recommendations may require a modified approach to some of the common practices in new product development but would result in more accessible and practical adjuvant-containing products.</p></abstract><kwd-group><kwd>adjuvants</kwd><kwd>formulation</kwd><kwd>future perspectives</kwd><kwd>vaccine development</kwd><kwd>natural product discovery</kwd><kwd>route of administration</kwd><kwd>design of experiments</kwd><kwd>systems immunology</kwd><kwd>mucosal vaccine</kwd><kwd>sustainability</kwd></kwd-group><funding-group><award-group><funding-source>National Institute of Allergy and Infectious Diseases</funding-source><award-id>R01AI135673</award-id></award-group><funding-statement>Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01AI135673 ($4.1 million). Moreover, 80% of the total project costs were financed with federal money. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-15-01850"><title>1. Introduction</title><p>Throughout the last two decades, there has been increasing focus on the discovery and translation of new immune-stimulating agents [<xref rid="B1-pharmaceutics-15-01850" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-15-01850" ref-type="bibr">2</xref>]. These compounds are often collectively referred to as adjuvants due to their precedent of use in vaccine development. In recent years, there has been an expansion in the application of adjuvants in oncology and other areas as our understanding and definition of adjuvants continue to grow [<xref rid="B3-pharmaceutics-15-01850" ref-type="bibr">3</xref>]. Adjuvants stimulate key cell types in the innate immune system and can influence the scale and class of immune response directed towards a given antigen or antigens [<xref rid="B4-pharmaceutics-15-01850" ref-type="bibr">4</xref>]. These innate immune cell subsets can then engage with effector cells in the adaptive immune system&#8212;e.g., T and B cells&#8212;which then mediate the development of cellular and humoral immunity, respectively. Adjuvants are also critical in the development of long-term memory cell populations, which in turn can lead to years-long protection [<xref rid="B5-pharmaceutics-15-01850" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-15-01850" ref-type="bibr">6</xref>]. In existing clinical products, adjuvants are often combined with recombinant subunit antigens, which are generally not sufficiently immunogenic to generate protective immune responses on their own [<xref rid="B7-pharmaceutics-15-01850" ref-type="bibr">7</xref>].</p><p>In recent years, there have been a handful of successful FDA approvals for vaccines containing new-to-market adjuvant systems, such as AS01, developed by GSK and included in Shingrix, Mosquirix, and Arexvy [<xref rid="B8-pharmaceutics-15-01850" ref-type="bibr">8</xref>]. However, despite its success, AS01 is based on techniques and technologies that were developed decades ago, and many reports note that vaccine adjuvants have some of the longest times to commercialization of any clinical product [<xref rid="B1-pharmaceutics-15-01850" ref-type="bibr">1</xref>]. A marked need exists for new adjuvant and immunostimulatory systems; however, there is also a need to better understand and plan for the barriers to translation earlier on in the adjuvant development pipeline.</p><p>The most widely used class of adjuvants is Alum, a generic term applied to aluminum salts, such as aluminum phosphate, aluminum hydroxide, aluminum hydroxyphosphate sulfate, and aluminum oxyhydroxide. Alum often serves the useful functions of adsorbing the protein antigen and mediating its presentation to innate immune cells in draining lymph nodes [<xref rid="B4-pharmaceutics-15-01850" ref-type="bibr">4</xref>,<xref rid="B9-pharmaceutics-15-01850" ref-type="bibr">9</xref>]. Aluminum-based adjuvants are present in many common vaccines, including the 9-valent HPV vaccine Gardasil and the Tdap vaccines (among many others) [<xref rid="B10-pharmaceutics-15-01850" ref-type="bibr">10</xref>]. Another common class of adjuvants is oil-in-water emulsions (e.g., MF59 and AS03), which typically include squalene in the oil phase, emulsifying agent(s), and other excipients [<xref rid="B4-pharmaceutics-15-01850" ref-type="bibr">4</xref>,<xref rid="B11-pharmaceutics-15-01850" ref-type="bibr">11</xref>]. Much like Alum adjuvants, squalene emulsions do not appear to engage a specific pattern recognition receptor (PRR) but instead mediate a local inflammatory response and increase the trafficking of antigens to draining lymph nodes [<xref rid="B12-pharmaceutics-15-01850" ref-type="bibr">12</xref>]. Notably, the tetravalent influenza vaccine Fluad contains MF59 [<xref rid="B10-pharmaceutics-15-01850" ref-type="bibr">10</xref>]. Similarly, saponin-based adjuvants, such as Matrix-M, offer pleiotropic modes of action, which tend to augment humoral and cellular immune responses. Likewise, the saponin QS-21 functions through an unknown receptor(s) but is known to trigger the inflammasome in model systems of immunogenicity [<xref rid="B13-pharmaceutics-15-01850" ref-type="bibr">13</xref>].</p><p>In contrast to the particulate adjuvant formulations described above, another class of clinical adjuvants includes specific chemical triggers of defined pathways. Most of these agents signal through PRRs, which are a critical part of the innate immune system and are involved in the detection of pathogen-associated molecular patterns (PAMPs) [<xref rid="B14-pharmaceutics-15-01850" ref-type="bibr">14</xref>]. The vaccine adjuvants monophosphoryl lipid A (MPL) and CpG 1018 are both highly characterized agonists of Toll-like receptors (TLRs) and help to shape the immune response towards a Th1-type quality [<xref rid="B10-pharmaceutics-15-01850" ref-type="bibr">10</xref>]. In many cases, adjuvant products comprise combinations that may include TLR ligands, saponins, and particulate formulations, such as AS01 in Shingrix and Arexvy (liposomal TLR4 agonist and QS-21), CpG 1018-Alum in Corbevax (TLR9 agonist adsorbed to Alum), and Alhydroxiquim-II in Covaxin (TLR7/8 agonist adsorbed to Alum) [<xref rid="B10-pharmaceutics-15-01850" ref-type="bibr">10</xref>].</p><p>Many unique adjuvants and adjuvant systems exist in preclinical development, as has been the case for many years. However, there continues to be a disconnect between the state of our understanding of adjuvants and our ability to deliver on that understanding in terms of clinical translation. At the same time, it is widely appreciated that adjuvants play a critical role in the development of long-lasting immunity and protection against target pathogens. This is most recently highlighted by the first generation of mRNA vaccines against SARS-CoV-2, which induced impressive initial antibody titers that rapidly waned [<xref rid="B15-pharmaceutics-15-01850" ref-type="bibr">15</xref>], a liability that adjuvanted vaccine candidates can improve upon [<xref rid="B16-pharmaceutics-15-01850" ref-type="bibr">16</xref>]. Moreover, much work is needed to establish adjuvant compatibility with next-generation vaccine platforms, including mRNA, DNA, and adeno-associated virus (AAV)-based vaccines. The gap between our understanding of the need for adjuvants and our ability to capitalize on their use in clinical products is related to multiple factors, including a lack of appreciation for the nuanced formulation considerations in vaccine adjuvant development, unclear rationale or parameters to select one adjuvant over another, and a failure to consider adjuvants with product potential until too late in the development process. At the same time, there are avenues for further development and discovery in adjuvant systems that will make them more accessible and simplify their integration into emerging vaccine systems.</p><p>From this perspective, we attempt to summarize what steps can be taken and what factors can be considered in the early stage of vaccine adjuvant design and development. We overview the importance of sustainable material sourcing, storage stability, alternate routes of administration, controlled release kinetics, and methods the vaccinologist can use to weigh these options while positioning their product toward clinical translation (<xref rid="pharmaceutics-15-01850-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec2-pharmaceutics-15-01850"><title>2. Sustainable Raw Materials</title><p>Natural product discovery generally refers to the practice of identifying compounds in existing natural reservoirs, usually plants, fungi, or bacteria [<xref rid="B17-pharmaceutics-15-01850" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-15-01850" ref-type="bibr">18</xref>]. In an idealized process, the specific active compound is identified via fractionation and a high-throughput bioassay [<xref rid="B17-pharmaceutics-15-01850" ref-type="bibr">17</xref>]. Next, a highly refined purified compound is generated, then physical and analytical chemistry techniques are employed to elucidate its active structure (e.g., nuclear magnetic resonance, time-of-flight mass spectrometry, and Raman spectroscopy). The active compound is synthetically produced via traditional organic chemistry techniques; then, medicinal chemistry approaches can be employed to refine the drug characteristics of the final active pharmaceutical ingredient (API). This approach generally relies on the eventual ability to fully synthesize the compound of interest, as chemical extraction of refined compounds is challenging and costly to scale.</p><p>Despite the associated costs and challenges, many existing adjuvants are derived directly from refined natural products. The saponin pool that QS-21 is refined from comes from <italic toggle="yes">Quillaja saponaria</italic>, the soap bark tree, which is native to a relatively small area of central Chile [<xref rid="B13-pharmaceutics-15-01850" ref-type="bibr">13</xref>]. Saponins from soap bark trees were first studied as immunostimulants in the first half of the 20th century and were later refined into Quil A, a heterogeneous saponin mixture that is presently used as an adjuvant in veterinary vaccines. In an effort to reduce the reactogenicity of Quil A, scientists identified and isolated the particularly active component QS-21 (named as the 21st peak on a chromatogram of Quil A) [<xref rid="B13-pharmaceutics-15-01850" ref-type="bibr">13</xref>]. The resulting QS-21 is a blend of two isomeric compounds differentiated by a terminal sugar structure [<xref rid="B19-pharmaceutics-15-01850" ref-type="bibr">19</xref>]. Despite the relatively low-yield industrial process, QS-21 is presently included in several vaccine products, including Shingrix, Mosquirix, and Arexvy, and is one of the multiple saponins in Nuvavoxid. As the number of QS-21-containing vaccines increases, alternative industrial processes to obtain QS-21 or suitable analog molecules could be required due to the limited availability of <italic toggle="yes">Quillaja saponaria</italic> and the poor extraction yields [<xref rid="B20-pharmaceutics-15-01850" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-15-01850" ref-type="bibr">21</xref>]. For example, synthetic biology approaches, such as expressing saponins in bioengineered organisms, may provide a more sustainable avenue to saponin production [<xref rid="B22-pharmaceutics-15-01850" ref-type="bibr">22</xref>]. Synthetic or semi-synthetic approaches to generating QS-21 analogs have also been demonstrated [<xref rid="B23-pharmaceutics-15-01850" ref-type="bibr">23</xref>].</p><p>Squalene provides another example of a natural product with a long history of use as an adjuvant vaccine component. All current squalene-based pharmaceutical products use refined oil derived from shark livers, including those containing MF59 or AS03 [<xref rid="B24-pharmaceutics-15-01850" ref-type="bibr">24</xref>]. While it is difficult to quantify how an increase in squalene-based vaccine adjuvant demand would impact shark populations, a more sustainable source of squalene or alternative analogs are desirable objectives. In recent years, many cosmetic companies have replaced shark squalene with olive-derived squalene. Olive squalene is concentrated in the skin and seeds of the fruit, meaning that it can be a byproduct of the global olive oil industry. Emulsified olive-derived squalene appears to maintain adjuvant properties in preclinical testing [<xref rid="B25-pharmaceutics-15-01850" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-15-01850" ref-type="bibr">26</xref>]. Other companies are working to distill squalene from the amaranth grain, which can be selectively cultivated and processed to increase squalene production [<xref rid="B27-pharmaceutics-15-01850" ref-type="bibr">27</xref>]. However, due in part to the difficulty and cost associated with extracting highly purified squalene from plants, plant-derived squalene has not yet been employed in any FDA-approved vaccine product [<xref rid="B24-pharmaceutics-15-01850" ref-type="bibr">24</xref>]. Other plant-derived terpenoid structures have also demonstrated adjuvant properties and merit further investigation [<xref rid="B28-pharmaceutics-15-01850" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-15-01850" ref-type="bibr">29</xref>]. Alternative routes to a more sustainable source of squalene-like molecules include synthetic biology and synthetic chemistry approaches. For example, non-shark squalene or squalene analog emulsions obtained using bioengineered yeast and/or synthetic chemistry have demonstrated equivalent or improved adjuvant activity compared to shark squalene emulsions [<xref rid="B28-pharmaceutics-15-01850" ref-type="bibr">28</xref>,<xref rid="B30-pharmaceutics-15-01850" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-15-01850" ref-type="bibr">31</xref>]. These approaches have the advantage of existing infrastructure in microbial fermentation and industrial chemical engineering. An added benefit of generating analog structures is that structure-function relationships can help elucidate features important for improved adjuvant activity in emulsions containing squalene-like molecules [<xref rid="B28-pharmaceutics-15-01850" ref-type="bibr">28</xref>].</p><p>MPL, a TLR4 agonist derived from <italic toggle="yes">Salmonella minnesota</italic>, was the first TLR agonist to be used in approved vaccines. The manufacturing process of MPL results in a heterogeneous mixture of compounds with different numbers of acyl chains, each of which may have different adjuvant properties [<xref rid="B32-pharmaceutics-15-01850" ref-type="bibr">32</xref>]. In contrast, synthetic TLR4 agonists offer highly pure single constructs with structures optimized for human TLR4 activity. Several synthetic TLR4 ligands as components of vaccine adjuvant formulations are undergoing clinical testing [<xref rid="B33-pharmaceutics-15-01850" ref-type="bibr">33</xref>]. However, other synthetic TLR ligands have already reached commercial product approval, including CpG 1018 (TLR9) in the hepatitis B vaccine Heplisav-B and, in some geographies, Alhydroxiquim-II (TLR7/8) in the SARS-CoV-2 vaccine Covaxin. In addition to TLR ligands, other synthetic PRR ligands, such as trehalose dibehenate (TDB), a ligand of the C-type lectin receptor Mincle, have advanced to clinical testing [<xref rid="B34-pharmaceutics-15-01850" ref-type="bibr">34</xref>]. Synthetic ligands for TLRs and other PRRs offer well-defined structures for precisely engineering the adjuvant properties of next-generation vaccines.</p><p>The above examples represent a range of adjuvant types and sources but are not intended to be comprehensive. Many other types of molecular and particulate adjuvants are in development. Nevertheless, regardless of the type of adjuvant and whether it is obtained from natural or synthetic sources, raw material sustainability must be a primary consideration.</p></sec><sec id="sec3-pharmaceutics-15-01850"><title>3. Thermostability</title><p>Much has been written elsewhere about vaccine cold-chain storage and the need for thermostable vaccine products to meet global vaccine needs [<xref rid="B35-pharmaceutics-15-01850" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-15-01850" ref-type="bibr">36</xref>], which is highlighted by the poor stability profile of mRNA-based COVID-19 vaccines that made them challenging to access in many areas [<xref rid="B37-pharmaceutics-15-01850" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-15-01850" ref-type="bibr">38</xref>]. Thermostability generally refers to the ability of the product to remain stable at ambient temperatures for sufficient amounts of time. Because of the logistical challenges of maintaining cold-chain transport, as much as 50% of vaccine doses are rendered unusable before administration in many low- and middle-income countries [<xref rid="B39-pharmaceutics-15-01850" ref-type="bibr">39</xref>]. In particular, more effort is needed in the development of thermostable adjuvant-containing vaccines [<xref rid="B39-pharmaceutics-15-01850" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-15-01850" ref-type="bibr">40</xref>]. Generating a thermostabilized product often necessitates reducing the water activity of a product to slow the rate of hydrolysis and other aqueous-phase decomposing processes, which are the major driving forces in antigen and adjuvant degradation [<xref rid="B41-pharmaceutics-15-01850" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-15-01850" ref-type="bibr">42</xref>]. This is often accomplished by generating a dried product, generally either through lyophilization or spray drying [<xref rid="B42-pharmaceutics-15-01850" ref-type="bibr">42</xref>]. However, transforming liquid adjuvant formulations into solid-state formulations with enhanced thermostability is not a trivial endeavor due to the complexities of adjuvant particulate structures. It is, therefore, worthwhile to consider optimizing formulations for enhanced thermostability early in development. The generation of solid-state materials is generally achieved via some form of drying technology, such as lyophilization or spray drying [<xref rid="B43-pharmaceutics-15-01850" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-15-01850" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-15-01850" ref-type="bibr">45</xref>]. Recent progress in applying such techniques to generate thermostable adjuvant formulations has been encouraging. For instance, a thermostable lyophilized presentation of a vaccine composition consisting of a protein antigen and an oil-in-water emulsion containing a synthetic TLR4 ligand was shown to maintain or even improve the safety and immunogenicity profile of the non-thermostable vaccine in a Phase 1 clinical trial of a GLA-SE adjuvanted subunit tuberculosis vaccine [<xref rid="B46-pharmaceutics-15-01850" ref-type="bibr">46</xref>]. The emerging class of nucleic acid-based adjuvants, such as TLR3 and RIG-I agonists, is likely to benefit greatly from dried preparations due to its relatively poor liquid stability compared to its improved stability in a dried state [<xref rid="B47-pharmaceutics-15-01850" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-15-01850" ref-type="bibr">48</xref>]. Alternative strategies to generate solid formulations include entrapment in an implant or microneedle patch, which may in turn provide controlled release benefits [<xref rid="B49-pharmaceutics-15-01850" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-15-01850" ref-type="bibr">50</xref>]. In any case, by prioritizing thermostability in new adjuvant-containing vaccines, more global markets may become accessible, which has clear benefits from economic, ethical, and global health perspectives.</p></sec><sec id="sec4-pharmaceutics-15-01850"><title>4. Alternative Routes of Delivery</title><p>Mucosal immunology is a somewhat less-explored field than systemic immunity, despite the mucosal route of infection for many infectious diseases. Each major mucosal system, including the urogenital, respiratory, and gastrointestinal tracts, has its own unique combination of defensive structures and effector cell populations. A large body of evidence demonstrates that vaccines delivered mucosally, such as the pulmonary or oral route, lead to immunological outcomes that are unique from systemically delivered products [<xref rid="B51-pharmaceutics-15-01850" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-15-01850" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-15-01850" ref-type="bibr">53</xref>]. Moreover, mucosal immune responses generated by mucosally delivered vaccines may be more effective in preventing infection for some indications [<xref rid="B53-pharmaceutics-15-01850" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-15-01850" ref-type="bibr">54</xref>]. Currently, there are some approved vaccines delivered by the oral or nasal route, but these are usually live-attenuated pathogens that do not contain extrinsic adjuvants. SARS-CoV-2 has generated even greater interest in the potential for mucosal delivery of vaccines [<xref rid="B55-pharmaceutics-15-01850" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-15-01850" ref-type="bibr">56</xref>]. However, several challenges must be overcome for more widespread adoption of mucosally delivered adjuvant-containing vaccines, including issues associated with absorption, toxicity, and administration technique.</p><p>The absorption of intact biomolecules across mucous membranes has been a clinical challenge for decades. Compared to parenterally dosed vaccine products that offer immediate bioavailability, only a fraction of mucosally administered material may successfully pass through epithelial tissue to generate a productive interaction with the effector cell populations residing below. This is especially true for mucosally delivered biologics, such as protein antigens or nucleic acids, which often have single-digit bioavailability percentages, even in advantageous mouse models [<xref rid="B57-pharmaceutics-15-01850" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-15-01850" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-15-01850" ref-type="bibr">59</xref>]. This low permeability stems from the relative lack of diffusion of large biomolecules across intact epithelial tissue, in addition to ubiquitous chemical and enzymatic proteolysis. In this regard, pulmonary dosage forms may behave more favorably due to a large surface area, a high degree of vascularization, and relatively thin mucosal barriers [<xref rid="B60-pharmaceutics-15-01850" ref-type="bibr">60</xref>]. In any case, mucosal adjuvant formulation development efforts may be needed to target cell uptake by resident antigen-presenting cells, which can sample antigens from across the epithelial barrier and then present them to effector subsets in the draining lymph node. Optimization of particle size and material properties are often exploited to achieve the desired tissue deposition [<xref rid="B61-pharmaceutics-15-01850" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-15-01850" ref-type="bibr">62</xref>].</p><p>Due to the issue of potential toxicity of mucosally delivered vaccine adjuvants, additional considerations must be taken into account compared to parenteral delivery. Most adjuvants generate some kind of local inflammation, which, depending on the individual and the product, could result in some short-term local or systemic reactogenicity [<xref rid="B63-pharmaceutics-15-01850" ref-type="bibr">63</xref>]. This disruption to tissue homeostasis is more pronounced in mucosal tissues, such as the lung or nose, where there might be more acutely undesirable side effects due to epithelial tissue inflammation. For this reason, the inclusion of adjuvants in mucosal vaccines is challenging because, while there is a need to elicit potent localized immune responses, there is also a more overt risk to doing so. The widely publicized experience with a nasally delivered inactivated influenza vaccine containing a bacterial toxoid adjuvant that caused Bell&#8217;s palsy in some recipients provides an unfortunate warning lesson in this regard [<xref rid="B64-pharmaceutics-15-01850" ref-type="bibr">64</xref>].</p><p>Finally, mucosally delivered vaccine and adjuvant preparations need to take the administration technique/device into account. Because of their limited application in current clinical products, new vaccine dosing methods will pose an adoption challenge. Intramuscular injections are a well-defined and ubiquitous means of administering vaccines, which offers clarity to both the patient and provider that the vaccine was administered successfully. In contrast, correct and incorrect user techniques may occur with equal frequency in nasal or pulmonary delivery [<xref rid="B65-pharmaceutics-15-01850" ref-type="bibr">65</xref>]. The absorption of oral products is similarly challenging and may be affected by a host of factors, including an individual&#8217;s diet before/after vaccination, microbiome status, enteropathy, stress, or presence of enteric pathogens or other conditions, such as inflammatory bowel disease [<xref rid="B66-pharmaceutics-15-01850" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-15-01850" ref-type="bibr">67</xref>]. In any case, it is essential that device compatibility with the adjuvant formulation is comprehensively assessed so that optimal delivery performance can be achieved [<xref rid="B62-pharmaceutics-15-01850" ref-type="bibr">62</xref>].</p><p>In summary, emerging adjuvant systems hoping to capitalize on the benefits of mucosal administration need to be evaluated thoroughly by taking the above factors into account. Thus, it is unlikely that an adjuvant formulation that has been designed for intramuscular use will automatically be optimized for mucosal delivery without some modifications to the composition. Furthermore, there must be a clear benefit demonstrated compared to more traditional delivery approaches that justifies the need for investing in mucosal delivery development efforts. For example, for vaccines against highly contagious respiratory pathogens, such as SARS-CoV-2 or influenza, an obvious added value would be if an adjuvanted vaccine could induce sterilizing immunity at the site of infection rather than being limited to primarily reducing disease severity.</p></sec><sec id="sec5-pharmaceutics-15-01850"><title>5. Control of Exposure Duration and Kinetics</title><p>In recent years, a number of reports have looked at the use of implantable controlled-release systems as a means to control the kinetics of vaccine antigen and adjuvant exposure. In general, extended, sustained, or pulsatile exposure to vaccine components over the course of weeks to months can improve the potency of an immune response and support the development of a broadly neutralizing antibody response [<xref rid="B68-pharmaceutics-15-01850" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-15-01850" ref-type="bibr">69</xref>]. This is especially relevant when developing vaccines against highly challenging pathogens, such as HIV [<xref rid="B70-pharmaceutics-15-01850" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceutics-15-01850" ref-type="bibr">71</xref>]. These implantable systems also have the potential to enable single-intervention vaccine regimens, eliminating the need for booster doses [<xref rid="B72-pharmaceutics-15-01850" ref-type="bibr">72</xref>]. There has also been extensive preclinical research into the use of intertumoral implantation of extended delivery systems for immune-oncology agents, with and without surgical resection, as a means to improve the efficacy of cancer immunotherapies [<xref rid="B73-pharmaceutics-15-01850" ref-type="bibr">73</xref>]. While our mechanistic understanding of these controlled-release systems is still evolving, it is generally thought that prolonged exposure to an antigen at draining lymph nodes leads to the development of more mature T and B effector cell responses [<xref rid="B74-pharmaceutics-15-01850" ref-type="bibr">74</xref>].</p><p>Controlled-release systems are generally designed for use with protein subunit antigens, and many have incorporated adjuvants to enhance the immunogenicity of these vaccines. To this end, many adjuvants have been included in a number of controlled-release vaccine systems, but most are off-the-shelf materials as opposed to fit-for-purpose compositions, including MPL, Alum, and CpG (among others) [<xref rid="B75-pharmaceutics-15-01850" ref-type="bibr">75</xref>]. These adjuvants, while effective, are unlikely to be optimal in the unique kinetics of a controlled-release system without additional modification. It is, therefore, worthwhile to test adjuvant platforms in the context of extended-release systems now so that, once the technology reaches clinical maturity, there will be front-runner adjuvants that could be applied in a second-generation product.</p><p>From a design perspective, implantable vaccines that have an active lifespan of weeks to months would be best served by a biodegradable material; otherwise, the requirement for removal of the device defeats many potential patient benefits. To this end, many biodegradable materials have been explored, including poly(D,L-lactic acid-co-glycolic acid) and polyanhydride as implants and various materials in gels, such as a variety of polyester and polyethylene block-copolymers, polysaccharide polymers like alginate or chitosan, synthetic peptide scaffolds, and cellulose derivatives (among others) [<xref rid="B75-pharmaceutics-15-01850" ref-type="bibr">75</xref>]. From a use standpoint, vaccine products, in general, are dependent on high uptake in relevant populations, meaning that dosing procedures that are more complex than a standard percutaneous injection will be more challenging to market [<xref rid="B76-pharmaceutics-15-01850" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-15-01850" ref-type="bibr">77</xref>]. For this reason, shear-thinning or in situ crosslinking materials are likely to have a market advantage over solid form factors that will require more complex outpatient procedures to place correctly [<xref rid="B75-pharmaceutics-15-01850" ref-type="bibr">75</xref>]. A potential advantage of these novel polymer-gel systems is that adjuvants can interact directly with the chemistry of the material to better synchronize release with a protein antigen [<xref rid="B78-pharmaceutics-15-01850" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-15-01850" ref-type="bibr">79</xref>]. Another approach is to use aluminum oxyhydroxide as a carrier for both the protein antigen and an anionic adjuvant, linking the release of both components [<xref rid="B72-pharmaceutics-15-01850" ref-type="bibr">72</xref>,<xref rid="B80-pharmaceutics-15-01850" ref-type="bibr">80</xref>]. Lastly, the largest hurdle adjuvant-containing systems will face is the regulatory challenge posed by establishing safety profiles for long-term exposure to inflammatory compounds in healthy populations. Extended exposure to adjuvants is likely to be a concern for both regulatory bodies and patients, so a very high bar for safety must be achieved in preclinical and early clinical studies. Indeed, long-term exposure to even sub-therapeutic amounts of pro-inflammatory compounds might have unintended risks [<xref rid="B68-pharmaceutics-15-01850" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-15-01850" ref-type="bibr">69</xref>]. These concerns are of course different in the field of oncology, where sustained systemic exposure to one or even multiple pro-inflammatory immune oncology drugs is becoming a standard of care for many indications [<xref rid="B81-pharmaceutics-15-01850" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceutics-15-01850" ref-type="bibr">82</xref>]. So, there is a reason to anticipate that a tumor-targeting vaccine implant may be the first to market, with subsequent prophylactic vaccination efforts for HIV or other difficult-to-target pathogens following.</p></sec><sec id="sec6-pharmaceutics-15-01850"><title>6. Combining Multiple Adjuvants and Vaccine Platforms</title><p>The success of the AS01 adjuvant system has demonstrated the potential clinical value to be realized with combinations of immunostimulants. AS01 contains the TLR4 agonist MPL and the fractionated saponin QS-21, formulated in a liposome that is admixed with or used to reconstitute the vaccine antigen [<xref rid="B83-pharmaceutics-15-01850" ref-type="bibr">83</xref>]. Studies have shown that AS01 benefits from an inherent synergy between the two agonists, leading to enhancements in both cellular and humoral immunity [<xref rid="B84-pharmaceutics-15-01850" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-15-01850" ref-type="bibr">85</xref>]. Interestingly, AS01 has often outperformed AS02 in clinical testing, notably in the development process of the now WHO-prequalified malaria vaccine Mosquirix, even though AS02 also contains MPL and QS-21 but is formulated in an oil-in-water emulsion [<xref rid="B86-pharmaceutics-15-01850" ref-type="bibr">86</xref>]. Thus, it is critical to consider not only the activity of each immunostimulant separately but also how they function together, how best to formulate them, and how the adjuvant formulation interacts with the vaccine antigen. Regardless of the actual components, the goal of adjuvant systems that combine multiple immunostimulants is to generate a complementary immune response without approaching the reactogenicity that might arise from using higher doses of a single immunostimulant. This requires identifying a synergistic effect between two agonists, which is most likely to occur between agonists that act in at least a partially orthogonal manner or target different cell types, as opposed to the additive effect that would be observed between two agonists that act along identical pathways. For instance, MPL and QS-21 are thought to act through complementary immunomodulatory pathways, resulting in a synergistic combination. Many other multi-agonist combinations have been trialed in preclinical models, notably the nucleic acid-based adjuvants CpG and 2&#8242;3&#8242;-cGAMP and the TLR4 agonist GLA with the TLR7/8 agonist 3M-052 [<xref rid="B87-pharmaceutics-15-01850" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-15-01850" ref-type="bibr">88</xref>]. Formulations of particulate adjuvants (such as Alum or squalene emulsion) with TLR ligands should also be considered combination adjuvants, as well as delivery vehicles for adsorbed agonists and/or antigens (e.g., AS04 and GLA-SE). Alum, in particular, is effective at binding protein antigens and molecular agonists and facilitates the codelivery of both to relevant immune populations in the draining lymph node, such as in the HPV vaccine Cervarix [<xref rid="B89-pharmaceutics-15-01850" ref-type="bibr">89</xref>].</p><p>Until recently, any given infectious disease had only a few commercial vaccines, and at any given time, most of the available vaccines for that disease used similar modalities (live attenuated, whole killed virus, subunit, virus-like particle, etc.). In the wake of the 2019 coronavirus pandemic, where nucleic acid and adenoviral vector vaccines both reached global markets alongside more traditional protein subunit or inactivated virus vaccines, there were expanded opportunities to consider how different vaccine modalities may interact with each other. Similar to how components of combination adjuvants, such as AS01, have an innate synergy, leading to more effective immune responses, it is reasonable that different vaccine modalities might also demonstrate beneficial complementarity. These kinds of vaccine schedules, where an individual receives different products between the prime and subsequent boost immunizations, are generally referred to as heterologous combinations [<xref rid="B90-pharmaceutics-15-01850" ref-type="bibr">90</xref>,<xref rid="B91-pharmaceutics-15-01850" ref-type="bibr">91</xref>]. The data obtained from heterologous COVID-19 vaccine regimens have generally focused on the near-term immunogenic profile, where the highly potent mRNA vaccines appear to be the top performers. However, it has become clear, in the context of SARS-CoV-2, that long-lasting protective immune memory has been more elusive to achieve with the current vaccines, particularly in the presence of rapidly mutating virus strains [<xref rid="B92-pharmaceutics-15-01850" ref-type="bibr">92</xref>]. In some cases, other vaccine platforms, such as appropriately adjuvanted subunit proteins or nanoparticle presentations, may provide distinct advantages, such as increased durability or breadth [<xref rid="B16-pharmaceutics-15-01850" ref-type="bibr">16</xref>,<xref rid="B93-pharmaceutics-15-01850" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceutics-15-01850" ref-type="bibr">94</xref>]. By presenting a combination of antigen types and structures in different vaccine platforms, including adjuvants where appropriate, it may be possible to better shape the quality of the final immune response [<xref rid="B95-pharmaceutics-15-01850" ref-type="bibr">95</xref>]. Even simultaneous administration of multiple vaccine modalities may be worth considering [<xref rid="B96-pharmaceutics-15-01850" ref-type="bibr">96</xref>]. However, the efficacy of mRNA-based vaccines may be suppressed when dosed along potent activators of type-one interferons (e.g., TLR3, TLR7/8, TLR9, STING, and RIG-I agonists) due to a reduction in protein expression [<xref rid="B97-pharmaceutics-15-01850" ref-type="bibr">97</xref>,<xref rid="B98-pharmaceutics-15-01850" ref-type="bibr">98</xref>,<xref rid="B99-pharmaceutics-15-01850" ref-type="bibr">99</xref>]. Nevertheless, there is potential that orthogonal immune potentiators might improve the limited durability of existing mRNA vaccines. To this end, an increased understanding of the interaction between different adjuvants, vaccine modalities, and routes of delivery might improve our ability to respond to pandemics.</p><p>Another approach to heterologous vaccination is alternating the route of administration to generate more effective mucosal immunity. This kind of &#8220;prime and pull&#8221; strategy was first described as a means to improve T cell responses in the lower female genital tract to a herpes simplex virus 2 (HSV2) subunit vaccine [<xref rid="B100-pharmaceutics-15-01850" ref-type="bibr">100</xref>]. The theory is that by first vaccinating via a conventional route (i.e., intramuscular) to elicit a mature systemic T cell response, peripheral T cell populations can then be recruited to mucosal sites using the local delivery of chemokines or other adjuvants. This approach has recently been applied as a therapeutic vaccine candidate in an animal model of HSV2 and demonstrated that the prime and pull strategy was more effective than either the systemic or mucosal approach in isolation [<xref rid="B101-pharmaceutics-15-01850" ref-type="bibr">101</xref>]. In addition to providing protection in the urogenital tract, prime and pull strategies have been effective in animal models of nasal, pulmonary, and ocular infection [<xref rid="B102-pharmaceutics-15-01850" ref-type="bibr">102</xref>,<xref rid="B103-pharmaceutics-15-01850" ref-type="bibr">103</xref>,<xref rid="B104-pharmaceutics-15-01850" ref-type="bibr">104</xref>,<xref rid="B105-pharmaceutics-15-01850" ref-type="bibr">105</xref>].</p><p>The necessary collaborations between vaccine manufacturers required to clinically evaluate these combinations could present substantial complexities; however, similar cross-branded combinations are commonly employed in oncology and are often beneficial to both manufacturers and patients [<xref rid="B106-pharmaceutics-15-01850" ref-type="bibr">106</xref>]. Given that some technologies will be first to market, it could be advantageous to design later products to provide complementary boost responses to the initial products. On the other hand, there is a risk that heterologous combinations might be ineffectual. In the context of the COVID-19 pandemic, it was shown in a small clinical cohort that individuals who received the BNT162b2 mRNA vaccine followed by the Novavax subunit boost generated a less substantial immune response than patients who received the BNT162b2 vaccine as a prime and boost. However, patients who first received the Oxford adenovirus vaccine, followed by the Novavax vaccine, outperformed groups who only received the BNT162b2 and/or Moderna mRNA vaccines in terms of T cell activity [<xref rid="B91-pharmaceutics-15-01850" ref-type="bibr">91</xref>]. This suggests that for difficult indications, considering heterologous combination products earlier on in vaccine development would allow for optimizing each individual product to achieve a subset of clinical endpoints rather than expecting comprehensive immune protection from each product on its own. In the context of pandemic preparedness, this approach might mean that early-stage products are focused on generating strong systemic humoral immunity to reduce disease severity, whereas subsequent products can be designed to emphasize enhanced durability or mucosal responses (<xref rid="pharmaceutics-15-01850-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec7-pharmaceutics-15-01850"><title>7. Optimization via Aggregate Metrics</title><p>The increased efficacy of AS01-based adjuvants compared to AS02 is somewhat surprising considering the well-accepted adjuvant properties of squalene emulsions, even without the addition of receptor agonists, and the generally immune inert nature of conventional liposomes [<xref rid="B86-pharmaceutics-15-01850" ref-type="bibr">86</xref>,<xref rid="B107-pharmaceutics-15-01850" ref-type="bibr">107</xref>,<xref rid="B108-pharmaceutics-15-01850" ref-type="bibr">108</xref>]. This suggests that the immune response generated from multiple immune stimulants may not be well modeled by a simple linear combination of the inputs. In practice, the mechanistic interplay between different immunostimulants is often challenging to define fully, and empirical studies remain the typical approach for adjuvant selection. However, characterizing immune responses to a combination of immunostimulants might be better achieved using tools and models built for complex physical systems, such as those found in digital signal processing or microscopy, where the specific underlying features that dictate the change from a signal input to output are governed by an empirical state-space model [<xref rid="B109-pharmaceutics-15-01850" ref-type="bibr">109</xref>]. State-space models and similar control theory techniques, such as transfer function analysis, are used across multiple engineering fields in the development of new processes or products as a way to predict performance during the design process [<xref rid="B110-pharmaceutics-15-01850" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceutics-15-01850" ref-type="bibr">111</xref>]. Alternatively, these models can be derived empirically from systems using specific test signals [<xref rid="B112-pharmaceutics-15-01850" ref-type="bibr">112</xref>]. This approach is most useful when systems can be approximated as linear time-invariant (LTI) systems, meaning that multiple inputs can be condensed into a linear combination of inputs and that the system state does not vary as a function of time [<xref rid="B113-pharmaceutics-15-01850" ref-type="bibr">113</xref>]. In the case of immune responses to adjuvants, the immune system is known to be highly non-linear, as exemplified by synergies and anti-synergies between different immunostimulants, and immune responses are highly dynamic and time-variant, as exemplified by immune memory as well as T cell exhaustion and other metabolic phenomena. These complications mean that modeling of the immune system is unlikely to completely replace empirical adjuvant screening; however, techniques such as systems immunology and statistical design of experiments (DoE) might improve the efficiency of the adjuvant selection process.</p><p>Systems immunology, the study of immune interactions on a pathway and cell/tissue level in response to different stimuli, has been a remarkable tool to discern how signals are propagated through the immune system and uncover unknown mechanisms of action for immune agonists [<xref rid="B114-pharmaceutics-15-01850" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceutics-15-01850" ref-type="bibr">115</xref>]. Like other clinical systems biology approaches, systems immunology seeks to maximize the amount of data that can be generated from minimal biological samples, most often peripheral blood. Techniques vary depending on the goals of the study but often include mass cytometry, single-cell transcriptomics and proteomics, bead-based analysis of soluble factors (i.e., Luminex assays), and more conventional readouts, such as antibody titer and breadth. These high-dimensional datasets are then analyzed using bioinformatics techniques and machine learning algorithms to build models that enable hypothesis testing and forecasting [<xref rid="B115-pharmaceutics-15-01850" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceutics-15-01850" ref-type="bibr">116</xref>]. Systems immunology has provided insights on a range of products, from predicting clinical responses to the yellow fever vaccine to clarifying cellular responses to the BNT162b2 mRNA vaccine [<xref rid="B117-pharmaceutics-15-01850" ref-type="bibr">117</xref>,<xref rid="B118-pharmaceutics-15-01850" ref-type="bibr">118</xref>]. For example, the B cell responses to the yellow fever vaccine can be correlated almost 1:1 to the expression of the TNFRS17 B cell growth factor receptor, which can be measured as soon as 7 days after vaccination as a more accelerated means of determining successful vaccination than traditional antibody titers [<xref rid="B117-pharmaceutics-15-01850" ref-type="bibr">117</xref>]. Systems analysis has also been applied clinically to better understand the mechanism of action and underlying kinetic differences between seasonal influenza vaccines with or without the addition of MF59 [<xref rid="B119-pharmaceutics-15-01850" ref-type="bibr">119</xref>]. These approaches provide an unprecedented ability to characterize immune responses and even confirm the immunogenicity of vaccines weeks to months before more conventional methods, such as antibody titer. Such systems vaccinology approaches will likely have an increasing impact on assessing immune response profiles in clinical studies of experimental vaccines and adjuvants [<xref rid="B1-pharmaceutics-15-01850" ref-type="bibr">1</xref>,<xref rid="B120-pharmaceutics-15-01850" ref-type="bibr">120</xref>].</p><p>Because of the large amount of data output that can be measured via systems immunology methods, and the large number of input factors that can be considered in adjuvant design and dosing, techniques are needed that can simultaneously account for and optimize multiple parameters at once. These techniques, especially ones that would be useful in early measurements of human immune responses (i.e., a Phase 0 study), could derisk future clinical studies [<xref rid="B121-pharmaceutics-15-01850" ref-type="bibr">121</xref>]. A method commonly employed by formulation scientists and engineers is the DoE approach [<xref rid="B122-pharmaceutics-15-01850" ref-type="bibr">122</xref>,<xref rid="B123-pharmaceutics-15-01850" ref-type="bibr">123</xref>]. DoE is a method to optimize experimental efficiency and multiple input parameters simultaneously. By applying a subset of the input space, researchers can use their empirical results to extrapolate toward the larger output space, often referred to as a response surface [<xref rid="B124-pharmaceutics-15-01850" ref-type="bibr">124</xref>,<xref rid="B125-pharmaceutics-15-01850" ref-type="bibr">125</xref>]. Optimized combinations of inputs are determined by applying desirability weights to each output and running an optimization algorithm on the resulting response surface to identify a set of inputs that will yield a desired set of outputs. DoE is a prospective method, meaning that the experimental groups are designed via a statistical tool set before the study is carried out to minimize the total number of replicates and groups needed to capture the system response to the input parameters to the desired degree. Once the inputs and outputs are programed into the statistical software, a set of experimental conditions and sample sizes are generated that will enable a model of each output as a function of each input and potentially higher order combinations of inputs as a measurement of interactions [<xref rid="B122-pharmaceutics-15-01850" ref-type="bibr">122</xref>]. Depending on the needs of the researcher, this can be used to determine which input factors have an effect on the desired output and which input variables can be simplified in future studies [<xref rid="B126-pharmaceutics-15-01850" ref-type="bibr">126</xref>]. Alternatively, once the input set is refined, the output models can be used to identify the optimal conditions of each relevant input parameter. Because of the group-reduction nature of DoE, the optimal combination of input parameters might not be a group that was physically tested but rather inferred from the model of the system [<xref rid="B88-pharmaceutics-15-01850" ref-type="bibr">88</xref>,<xref rid="B127-pharmaceutics-15-01850" ref-type="bibr">127</xref>].</p><p>In the context of preclinical adjuvant development, DoE inputs could include the dose of one or more PRR agonists, the composition of formulation active ingredients and excipients (such as Alum, squalene emulsion, or liposomes), the frequency of booster administration, the route of delivery, etc. The outputs for this kind of system could be maximizing serum antibodies and cytokines, peripheral cellular activation via flow cytometric measurements, measurements derived from tissues sampled at the conclusion of the study (i.e., long-lived antibody-secreting cells in bone marrow, splenocyte/lymph node activation, mucosal antibodies), neutralizing antibody titers, upregulation of genes in systems immunology datasets, or even physicochemical stability of the adjuvant formulation. Other outputs could include minimizing reactogenicity or undesirable immune response signals (e.g., Th2 vs. Th1 cellular immunity). The outputs can be integrated into a single score for ranking various candidates using an aggregate tool such as the desirability index approach [<xref rid="B88-pharmaceutics-15-01850" ref-type="bibr">88</xref>]. A number of groups have demonstrated desirability index or DoE-based optimization in the development of preclinical and even clinical vaccine products, including the optimization of the ratio of 3M-052 and GLA in a preclinical <italic toggle="yes">Entamoeba histolytica</italic> vaccine candidate or the optimization of the excipient content and stability of a lyophilized subunit tuberculosis antigen with GLA-SE adjuvant that has now been validated in a Phase 1 clinical trial [<xref rid="B46-pharmaceutics-15-01850" ref-type="bibr">46</xref>,<xref rid="B88-pharmaceutics-15-01850" ref-type="bibr">88</xref>,<xref rid="B126-pharmaceutics-15-01850" ref-type="bibr">126</xref>,<xref rid="B127-pharmaceutics-15-01850" ref-type="bibr">127</xref>,<xref rid="B128-pharmaceutics-15-01850" ref-type="bibr">128</xref>,<xref rid="B129-pharmaceutics-15-01850" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceutics-15-01850" ref-type="bibr">130</xref>]. Applying the high-dimensional data that can be generated using systems vaccinology approaches together with the efficient multi-parameter optimization of DoE techniques enables extracting as much information as possible while minimizing the size of groups required for testing.</p></sec><sec sec-type="conclusions" id="sec8-pharmaceutics-15-01850"><title>8. Conclusions</title><p>Considering that many vaccines are well served by existing adjuvants, what benefit could new vaccine adjuvants address that is not currently met by existing products? One important practical point is access to the adjuvant. In many cases, it may not be possible to access existing adjuvants due to licensing restrictions, limited supply, or related business decisions. Additionally, new, rationally designed adjuvants might lead to more desirable immune response qualities or better meet the needs of specific populations or geographies. In any case, it is essential that the added value of any new adjuvant system be clearly benchmarked to well-accepted, widely available adjuvants, such as Alum or squalene emulsion [<xref rid="B131-pharmaceutics-15-01850" ref-type="bibr">131</xref>]. Another practical factor that should be considered early in the development of new adjuvant systems is the balance of simplicity and innovation. In general, most pharmaceutical systems benefit from being as simplified as possible, from formulation and composition to manufacturing and distribution. A simpler product that contains fewer ingredients, and is manufactured in fewer steps, has fewer potential points of failure, fewer risks of supply chain disruption, reduced regulatory burden, and a lower production cost. However, there are obvious benefits to mindfully accepting some additional risk or complication in order to generate a more effective product. For example, over the last 40 years, numerous HIV vaccine candidates based on standard approaches have failed [<xref rid="B132-pharmaceutics-15-01850" ref-type="bibr">132</xref>], so there is a clear need to innovate to develop new vaccine and adjuvant technologies to address these challenges. However, such innovations must still be globally accessible in terms of material availability, vaccine stability, dosing strategy, and scale of manufacturing. These factors need to be considered early on in development to ensure that clinical translation is feasible (see <xref rid="pharmaceutics-15-01850-box001" ref-type="boxed-text">Box 1</xref>).</p><p>Although vaccines containing novel adjuvants have historically been one of the most challenging products to bring to the clinic, multiple adjuvant-containing vaccines have been approved in the last ~15 years, with SARS-CoV-2 substantially accelerating this trend. Furthermore, initial clinical progress has been achieved in the development of thermostable vaccine adjuvant platforms as well as the implementation of systems immunology approaches to analyze clinical samples. In parallel to these clinical advancements, significant preclinical progress has been made regarding sustainable sourcing of adjuvant raw materials, alternative routes of adjuvant delivery, and control of vaccine and adjuvant delivery kinetics, providing new opportunities to optimize vaccine adjuvant design, development, and manufacturing. In general, vaccine adjuvant development is a highly contextual endeavor, and there is no one-size-fits-all solution. However, there is hope that progress in vaccine adjuvant development and accessibility can be accelerated further by taking into account the practical aspects of adjuvant development discussed here.</p><boxed-text id="pharmaceutics-15-01850-box001" position="float" orientation="portrait"><label>Box 1</label><caption><title>Summary of recommendations for new adjuvant development.</title></caption><list list-type="order"><list-item><p>Derisk the environmental and supply chain sustainability of materials. Consider alternate compounds or production methods to reduce dependency on animal or unsustainable sources.</p></list-item><list-item><p>Incorporate thermostability approaches early in development.</p></list-item><list-item><p>Define the need that a new adjuvant would address (e.g., mucosal immunity and durability of immunity) and tailor subsequent activities to this need.</p></list-item><list-item><p>Keep compositions as simple as possible but consider the added value of combination approaches when necessary.</p></list-item><list-item><p>Employ experimental design methods and systems immunology approaches to comprehensively characterize the immune profile of the new adjuvant.</p></list-item></list></boxed-text></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, C.B.F. and W.R.L.; writing&#8212;original draft preparation, C.B.F. and W.R.L.; writing&#8212;review and editing, C.B.F. and W.R.L.; visualization, W.R.L.; funding acquisition, C.B.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>C.B.F. is an inventor on numerous patents and patent applications claiming adjuvant and formulation compositions and methods. The funding agency had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-15-01850"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name></person-group><article-title>Emerging Concepts in the Science of Vaccine Adjuvants</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></element-citation></ref><ref id="B2-pharmaceutics-15-01850"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Lodaya</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Lofano</surname><given-names>G.</given-names></name></person-group><article-title>The Continued Advance of Vaccine Adjuvants&#8212;&#8216;We can work it out&#8217;</article-title><source>Semin. Immunol.</source><year>2020</year><volume>50</volume><fpage>101426</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2020.101426</pub-id><pub-id pub-id-type="pmid">33257234</pub-id></element-citation></ref><ref id="B3-pharmaceutics-15-01850"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luchner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reinke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milicic</surname><given-names>A.</given-names></name></person-group><article-title>TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>142</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13020142</pub-id><pub-id pub-id-type="pmid">33499143</pub-id><pub-id pub-id-type="pmcid">PMC7911620</pub-id></element-citation></ref><ref id="B4-pharmaceutics-15-01850"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hogenesch</surname><given-names>H.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Vaccine Adjuvants: Mechanisms of Action</article-title><source>Vaccine Development: From Concept to Clinic</source><person-group person-group-type="editor"><name name-style="western"><surname>Prasad</surname><given-names>A.K.</given-names></name></person-group><series>Drug Discovery Series</series><publisher-name>Royal Society of Chemistry</publisher-name><publisher-loc>London, UK</publisher-loc><year>2023</year><fpage>214</fpage><lpage>236</lpage></element-citation></ref><ref id="B5-pharmaceutics-15-01850"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burny</surname><given-names>W.</given-names></name><name name-style="western"><surname>Callegaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bechtold</surname><given-names>V.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fissette</surname><given-names>L.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>A.</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>943</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00943</pub-id><pub-id pub-id-type="pmid">28855902</pub-id><pub-id pub-id-type="pmcid">PMC5557780</pub-id></element-citation></ref><ref id="B6-pharmaceutics-15-01850"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fierens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fochesato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dendouga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Langlet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name><etal/></person-group><article-title>Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>1920</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400948</pub-id><pub-id pub-id-type="pmid">25024381</pub-id></element-citation></ref><ref id="B7-pharmaceutics-15-01850"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name></person-group><article-title>Recombinant Protein Vaccines, a Proven Approach against Coronavirus Pandemics</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>170</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.01.001</pub-id><pub-id pub-id-type="pmid">33421475</pub-id><pub-id pub-id-type="pmcid">PMC7788321</pub-id></element-citation></ref><ref id="B8-pharmaceutics-15-01850"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Godeaux</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chlibek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diez-Domingo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McElhaney</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Poder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puig-Barber&#224;</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>2087</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1501184</pub-id><pub-id pub-id-type="pmid">25916341</pub-id></element-citation></ref><ref id="B9-pharmaceutics-15-01850"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghimire</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Garside</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>J.M.</given-names></name></person-group><article-title>Alum Increases Antigen Uptake, Reduces Antigen Degradation and Sustains Antigen Presentation by DCs in Vitro</article-title><source>Immunol. Lett.</source><year>2012</year><volume>147</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2012.06.002</pub-id><pub-id pub-id-type="pmid">22732235</pub-id><pub-id pub-id-type="pmcid">PMC3477319</pub-id></element-citation></ref><ref id="B10-pharmaceutics-15-01850"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Facciol&#224;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Visalli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lagan&#224;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Pietro</surname><given-names>A.</given-names></name></person-group><article-title>An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>819</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10050819</pub-id><pub-id pub-id-type="pmid">35632575</pub-id><pub-id pub-id-type="pmcid">PMC9147349</pub-id></element-citation></ref><ref id="B11-pharmaceutics-15-01850"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Haensler</surname><given-names>J.</given-names></name></person-group><article-title>An Update on Safety and Immunogenicity of Vaccines Containing Emulsion-Based Adjuvants</article-title><source>Expert Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>747</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.811188</pub-id><pub-id pub-id-type="pmid">23885820</pub-id></element-citation></ref><ref id="B12-pharmaceutics-15-01850"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>A.</given-names></name></person-group><article-title>The Mechanism of Action of MF59&#8212;An Innately Attractive Adjuvant Formulation</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4341</fpage><lpage>4348</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.061</pub-id><pub-id pub-id-type="pmid">22682289</pub-id></element-citation></ref><ref id="B13-pharmaceutics-15-01850"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenbin Tuo</surname><given-names>D.Z.</given-names></name></person-group><article-title>QS-21: A Potent Vaccine Adjuvant</article-title><source>Nat. Prod. Chem. Res.</source><year>2016</year><volume>3</volume><fpage>e113</fpage><pub-id pub-id-type="doi">10.4172/2329-6836.1000e113</pub-id><pub-id pub-id-type="pmid">27213168</pub-id><pub-id pub-id-type="pmcid">PMC4874334</pub-id></element-citation></ref><ref id="B14-pharmaceutics-15-01850"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-Y.F.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.-R.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>T.-H.</given-names></name></person-group><article-title>Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>423</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14020423</pub-id><pub-id pub-id-type="pmid">35214155</pub-id><pub-id pub-id-type="pmcid">PMC8878135</pub-id></element-citation></ref><ref id="B15-pharmaceutics-15-01850"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notarte</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Guerrero-Arguero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Velasco</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Ver</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>M.H.S.</given-names></name><name name-style="western"><surname>Catahay</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Pastrana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Juszczyk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Torrelles</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Characterization of the Significant Decline in Humoral Immune Response Six Months Post-SARS-CoV-2 MRNA Vaccination: A Systematic Review</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>2939</fpage><lpage>2961</lpage><pub-id pub-id-type="doi">10.1002/jmv.27688</pub-id><pub-id pub-id-type="pmid">35229324</pub-id><pub-id pub-id-type="pmcid">PMC9088566</pub-id></element-citation></ref><ref id="B16-pharmaceutics-15-01850"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milligan</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Olstad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Mallory</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Munt</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lindesmith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Infant Rhesus Macaques Immunized against SARS-CoV-2 Are Protected against Heterologous Virus Challenge 1 Year Later</article-title><source>Sci. Transl. Med.</source><year>2023</year><volume>15</volume><fpage>eadd6383</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.add6383</pub-id><pub-id pub-id-type="pmid">36454813</pub-id><pub-id pub-id-type="pmcid">PMC9765459</pub-id></element-citation></ref><ref id="B17-pharmaceutics-15-01850"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wainwright</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Adelson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Braga</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Buenz</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Campana</surname><given-names>P.R.V.</given-names></name><name name-style="western"><surname>David</surname><given-names>B.</given-names></name><name name-style="western"><surname>Glaser</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Harata-Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Howes</surname><given-names>M.-J.R.</given-names></name><etal/></person-group><article-title>Future Directions for the Discovery of Natural Product-Derived Immunomodulating Drugs: An IUPHAR Positional Review</article-title><source>Pharmacol. Res.</source><year>2022</year><volume>177</volume><fpage>106076</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106076</pub-id><pub-id pub-id-type="pmid">35074524</pub-id></element-citation></ref><ref id="B18-pharmaceutics-15-01850"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Woods</surname><given-names>N.</given-names></name><name name-style="western"><surname>Niwasabutra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Acevedo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Igoli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Altwaijry</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Tusiimire</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Ferro</surname><given-names>V.A.</given-names></name></person-group><article-title>Natural Vaccine Adjuvants and Immunopotentiators Derived From Plants, Fungi, Marine Organisms, and Insects</article-title><source>Immunopotentiators in Modern Vaccines</source><publisher-name>Elsevier</publisher-name><publisher-loc>London, UK</publisher-loc><year>2017</year><fpage>211</fpage><lpage>229</lpage><isbn>978-0-12-804019-5</isbn></element-citation></ref><ref id="B19-pharmaceutics-15-01850"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis</article-title><source>Acc. Chem. Res.</source><year>2016</year><volume>49</volume><fpage>1741</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.6b00242</pub-id><pub-id pub-id-type="pmid">27568877</pub-id><pub-id pub-id-type="pmcid">PMC5032057</pub-id></element-citation></ref><ref id="B20-pharmaceutics-15-01850"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>Natural and Synthetic Saponins as Vaccine Adjuvants</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>222</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9030222</pub-id><pub-id pub-id-type="pmid">33807582</pub-id><pub-id pub-id-type="pmcid">PMC8001307</pub-id></element-citation></ref><ref id="B21-pharmaceutics-15-01850"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield</article-title><source>J. Chromatogr. A</source><year>2021</year><volume>1635</volume><fpage>461705</fpage><pub-id pub-id-type="doi">10.1016/j.chroma.2020.461705</pub-id><pub-id pub-id-type="pmid">33234294</pub-id><pub-id pub-id-type="pmcid">PMC7770036</pub-id></element-citation></ref><ref id="B22-pharmaceutics-15-01850"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>J.</given-names></name><name name-style="western"><surname>Orme</surname><given-names>A.</given-names></name><name name-style="western"><surname>El-Demerdash</surname><given-names>A.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L.B.B.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rejzek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Harkess</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Elucidation of the Pathway for Biosynthesis of Saponin Adjuvants from the Soapbark Tree</article-title><source>Science</source><year>2023</year><volume>379</volume><fpage>1252</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1126/science.adf3727</pub-id><pub-id pub-id-type="pmid">36952412</pub-id></element-citation></ref><ref id="B23-pharmaceutics-15-01850"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walkowicz</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Semisynthesis of Analogues of the Saponin Immunoadjuvant QS-21</article-title><source>Vaccine Adjuvants: Methods and Protocols</source><person-group person-group-type="editor"><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><publisher-name>Springer New York</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2017</year><fpage>45</fpage><lpage>71</lpage><isbn>978-1-4939-6445-1</isbn><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-6445-1_4</pub-id><pub-id pub-id-type="pmcid">PMC5120590</pub-id><pub-id pub-id-type="pmid">27718185</pub-id></element-citation></ref><ref id="B24-pharmaceutics-15-01850"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azevedo-Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>J.C.</given-names></name></person-group><article-title>From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>265</elocation-id><pub-id pub-id-type="doi">10.3390/ph15030265</pub-id><pub-id pub-id-type="pmid">35337064</pub-id><pub-id pub-id-type="pmcid">PMC8951290</pub-id></element-citation></ref><ref id="B25-pharmaceutics-15-01850"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gallorini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>G.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name></person-group><article-title>An Alternative Renewable Source of Squalene for Use in Emulsion Adjuvants</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6262</fpage><lpage>6268</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.067</pub-id><pub-id pub-id-type="pmid">21723355</pub-id></element-citation></ref><ref id="B26-pharmaceutics-15-01850"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Dutill</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Vedvick</surname><given-names>T.S.</given-names></name></person-group><article-title>Monitoring the Effects of Component Structure and Source on Formulation Stability and Adjuvant Activity of Oil-in-Water Emulsions</article-title><source>Colloids Surf. B Biointerfaces</source><year>2008</year><volume>65</volume><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2008.03.003</pub-id><pub-id pub-id-type="pmid">18440205</pub-id></element-citation></ref><ref id="B27-pharmaceutics-15-01850"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>K.C.</given-names></name></person-group><article-title>Assessment of Squalene Variability and Its Enhancement in Amaranthus Populations: With Application to Vaccine Development</article-title><source>Biotechnol. Appl. Biochem.</source><year>2022</year><volume>69</volume><fpage>2745</fpage><lpage>2752</lpage><pub-id pub-id-type="doi">10.1002/bab.2319</pub-id><pub-id pub-id-type="pmid">35032134</pub-id></element-citation></ref><ref id="B28-pharmaceutics-15-01850"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Kinsey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mohamath</surname><given-names>R.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Lykins</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>J.</given-names></name><name name-style="western"><surname>Argilla</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Semi-Synthetic Terpenoids with Differential Adjuvant Properties as Sustainable Replacements for Shark Squalene in Vaccine Emulsions</article-title><source>Npj Vaccines</source><year>2023</year><volume>8</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00608-y</pub-id><pub-id pub-id-type="pmid">36797262</pub-id><pub-id pub-id-type="pmcid">PMC9935550</pub-id></element-citation></ref><ref id="B29-pharmaceutics-15-01850"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Van Hoeven</surname><given-names>N.</given-names></name><name name-style="western"><surname>Granger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marlenee</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Soultanov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name></person-group><article-title>Vaccine Adjuvant Activity of Emulsified Oils from Species of the Pinaceae Family</article-title><source>Phytomedicine</source><year>2019</year><volume>64</volume><fpage>152927</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2019.152927</pub-id><pub-id pub-id-type="pmid">31465981</pub-id><pub-id pub-id-type="pmcid">PMC6790179</pub-id></element-citation></ref><ref id="B30-pharmaceutics-15-01850"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tateno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Srodulski</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Reedy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gawriluk</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kempinski</surname><given-names>C.F.</given-names></name></person-group><article-title>Synthetic Biology-Derived Triterpenes as Efficacious Immunomodulating Adjuvants</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>17090</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-73868-6</pub-id><pub-id pub-id-type="pmid">33051497</pub-id><pub-id pub-id-type="pmcid">PMC7553918</pub-id></element-citation></ref><ref id="B31-pharmaceutics-15-01850"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adlington</surname><given-names>K.</given-names></name><name name-style="western"><surname>El Harfi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title>Molecular Design of Squalene/Squalane Countertypes via the Controlled Oligomerization of Isoprene and Evaluation of Vaccine Adjuvant Applications</article-title><source>Biomacromolecules</source><year>2016</year><volume>17</volume><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.5b01285</pub-id><pub-id pub-id-type="pmid">26652915</pub-id></element-citation></ref><ref id="B32-pharmaceutics-15-01850"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moutaftsi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Windish</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Laughlin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e16333</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0016333</pub-id><pub-id pub-id-type="pmid">21298114</pub-id><pub-id pub-id-type="pmcid">PMC3027669</pub-id></element-citation></ref><ref id="B33-pharmaceutics-15-01850"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Current Status of Toll-Like Receptor 4 Ligand Vaccine Adjuvants</article-title><source>Immunopotentiators in Modern Vaccines</source><person-group person-group-type="editor"><name name-style="western"><surname>Schijns</surname><given-names>V.E.J.C.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2017</year><fpage>105</fpage><lpage>127</lpage><isbn>978-0-12-804019-5</isbn></element-citation></ref><ref id="B34-pharmaceutics-15-01850"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Juel</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cheeseman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Dohn</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kristiansen</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Korsholm</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>A.W.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of the Chlamydia Vaccine Candidate CTH522 Adjuvanted with CAF01 Liposomes or Aluminium Hydroxide: A First-in-Human, Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>1091</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30279-8</pub-id><pub-id pub-id-type="pmid">31416692</pub-id></element-citation></ref><ref id="B35-pharmaceutics-15-01850"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zehrung</surname><given-names>D.</given-names></name></person-group><article-title>Desirable Attributes of Vaccines for Deployment in Low-Resource Settings</article-title><source>J. Pharm. Sci.</source><year>2013</year><volume>102</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/jps.23352</pub-id><pub-id pub-id-type="pmid">23136115</pub-id></element-citation></ref><ref id="B36-pharmaceutics-15-01850"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lydon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zipursky</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tevi-Benissan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Djingarey</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Gbedonou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Youssouf</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Zaffran</surname><given-names>M.</given-names></name></person-group><article-title>Economic Benefits of Keeping Vaccines at Ambient Temperature during Mass Vaccination: The Case of Meningitis A Vaccine in Chad</article-title><source>Bull. World Health Organ.</source><year>2014</year><volume>92</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.2471/BLT.13.123471</pub-id><pub-id pub-id-type="pmid">24623901</pub-id><pub-id pub-id-type="pmcid">PMC3949534</pub-id></element-citation></ref><ref id="B37-pharmaceutics-15-01850"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>S.P.</given-names></name></person-group><article-title>Review of COVID-19 MRNA Vaccines: BNT162b2 and MRNA-1273</article-title><source>J. Pharm. Pract.</source><year>2022</year><volume>35</volume><fpage>947</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1177/08971900211009650</pub-id><pub-id pub-id-type="pmid">33840294</pub-id></element-citation></ref><ref id="B38-pharmaceutics-15-01850"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Roni</surname><given-names>M.A.</given-names></name></person-group><article-title>Challenges of Storage and Stability of MRNA-Based COVID-19 Vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1033</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9091033</pub-id><pub-id pub-id-type="pmid">34579270</pub-id><pub-id pub-id-type="pmcid">PMC8473088</pub-id></element-citation></ref><ref id="B39-pharmaceutics-15-01850"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>V.</given-names></name><name name-style="western"><surname>Baindara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A.</given-names></name></person-group><article-title>Thermostable Vaccines: An Innovative Concept in Vaccine Development</article-title><source>Expert Rev. Vaccines</source><year>2022</year><volume>21</volume><fpage>811</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1080/14760584.2022.2053678</pub-id><pub-id pub-id-type="pmid">35285366</pub-id></element-citation></ref><ref id="B40-pharmaceutics-15-01850"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Development of Thermostable Vaccine Adjuvants</article-title><source>Expert Rev. Vaccines</source><year>2021</year><volume>20</volume><fpage>497</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1080/14760584.2021.1902314</pub-id><pub-id pub-id-type="pmid">33724133</pub-id><pub-id pub-id-type="pmcid">PMC8292183</pub-id></element-citation></ref><ref id="B41-pharmaceutics-15-01850"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emami</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vatanara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Na</surname><given-names>D.H.</given-names></name></person-group><article-title>Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><elocation-id>131</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics10030131</pub-id><pub-id pub-id-type="pmid">30126135</pub-id><pub-id pub-id-type="pmcid">PMC6161129</pub-id></element-citation></ref><ref id="B42-pharmaceutics-15-01850"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emami</surname><given-names>F.</given-names></name><name name-style="western"><surname>Keihan Shokooh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mostafavi Yazdi</surname><given-names>S.J.</given-names></name></person-group><article-title>Recent Progress in Drying Technologies for Improving the Stability and Delivery Efficiency of Biopharmaceuticals</article-title><source>J. Pharm. Investig.</source><year>2023</year><volume>53</volume><fpage>35</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s40005-022-00610-x</pub-id><pub-id pub-id-type="pmcid">PMC9768793</pub-id><pub-id pub-id-type="pmid">36568503</pub-id></element-citation></ref><ref id="B43-pharmaceutics-15-01850"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Dutill</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>R.M.</given-names></name></person-group><article-title>Lyophilization of Adjuvanted Vaccines: Methods for Formulation of a Thermostable Freeze-Dried Product</article-title><source>Vaccine Adjuvants: Methods and Protocols</source><person-group person-group-type="editor"><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><comment>Methods in Molecular Biology</comment><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2017</year><fpage>215</fpage><lpage>226</lpage><isbn>978-1-4939-6445-1</isbn><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-6445-1_15</pub-id><pub-id pub-id-type="pmid">27718196</pub-id></element-citation></ref><ref id="B44-pharmaceutics-15-01850"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vehring</surname><given-names>R.</given-names></name></person-group><article-title>Spray Drying and Particle Engineering in Dosage Form Design for Global Vaccines</article-title><source>J. Aerosol Med. Pulm. Drug Deliv.</source><year>2022</year><volume>35</volume><fpage>121</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1089/jamp.2021.0056</pub-id><pub-id pub-id-type="pmid">35172104</pub-id></element-citation></ref><ref id="B45-pharmaceutics-15-01850"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Preston</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>T.W.</given-names></name></person-group><article-title>Stability of Lyophilized and Spray Dried Vaccine Formulations</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>171</volume><fpage>50</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.01.016</pub-id><pub-id pub-id-type="pmid">33484735</pub-id></element-citation></ref><ref id="B46-pharmaceutics-15-01850"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagawa</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>Goman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Frevol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blazevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tennant</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Day</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lemiale</surname><given-names>F.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of a Thermostable ID93&#8201;+&#8201;GLA-SE Tuberculosis Vaccine Candidate in Healthy Adults</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>1138</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36789-2</pub-id><pub-id pub-id-type="pmid">36878897</pub-id><pub-id pub-id-type="pmcid">PMC9988862</pub-id></element-citation></ref><ref id="B47-pharmaceutics-15-01850"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muramatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bajusz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Laczk&#243;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Karik&#243;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schreiner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lutwyche</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heyes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name></person-group><article-title>Lyophilization Provides Long-Term Stability for a Lipid Nanoparticle-Formulated, Nucleoside-Modified MRNA Vaccine</article-title><source>Mol. Ther.</source><year>2022</year><volume>30</volume><fpage>1941</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2022.02.001</pub-id><pub-id pub-id-type="pmid">35131437</pub-id><pub-id pub-id-type="pmcid">PMC8815268</pub-id></element-citation></ref><ref id="B48-pharmaceutics-15-01850"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.Y.L.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>M.Y.T.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>F.F.K.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>P.C.L.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>J.K.W.</given-names></name></person-group><article-title>Spray Freeze Drying of Small Nucleic Acids as Inhaled Powder for Pulmonary Delivery</article-title><source>Asian J. Pharm. Sci.</source><year>2018</year><volume>13</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2017.10.002</pub-id><pub-id pub-id-type="pmid">32104389</pub-id><pub-id pub-id-type="pmcid">PMC7032260</pub-id></element-citation></ref><ref id="B49-pharmaceutics-15-01850"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demuth</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Min</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>P.T.</given-names></name></person-group><article-title>Implantable Silk Composite Microneedles for Programmable Vaccine Release Kinetics and Enhanced Immunogenicity in Transcutaneous Immunization</article-title><source>Adv. Healthc. Mater.</source><year>2014</year><volume>3</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1002/adhm.201300139</pub-id><pub-id pub-id-type="pmid">23847143</pub-id><pub-id pub-id-type="pmcid">PMC3950936</pub-id></element-citation></ref><ref id="B50-pharmaceutics-15-01850"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creighton</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Woodrow</surname><given-names>K.A.</given-names></name></person-group><article-title>Microneedle-Mediated Vaccine Delivery to the Oral Mucosa</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>8</volume><fpage>1801180</fpage><pub-id pub-id-type="doi">10.1002/adhm.201801180</pub-id><pub-id pub-id-type="pmcid">PMC6476557</pub-id><pub-id pub-id-type="pmid">30537400</pub-id></element-citation></ref><ref id="B51-pharmaceutics-15-01850"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frizzell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Woodrow</surname><given-names>K.A.</given-names></name></person-group><article-title>Biomaterial Approaches for Understanding and Overcoming Immunological Barriers to Effective Oral Vaccinations</article-title><source>Adv. Funct. Mater.</source><year>2020</year><volume>30</volume><fpage>1907170</fpage><pub-id pub-id-type="doi">10.1002/adfm.201907170</pub-id></element-citation></ref><ref id="B52-pharmaceutics-15-01850"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanBenschoten</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Woodrow</surname><given-names>K.A.</given-names></name></person-group><article-title>Vaginal Delivery of Vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>178</volume><fpage>113956</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.113956</pub-id><pub-id pub-id-type="pmid">34481031</pub-id><pub-id pub-id-type="pmcid">PMC8722700</pub-id></element-citation></ref><ref id="B53-pharmaceutics-15-01850"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>R.W.</given-names></name></person-group><article-title>Mucosal Vaccines&#8212;Fortifying the Frontiers</article-title><source>Nat. Rev. Immunol.</source><year>2022</year><volume>22</volume><fpage>236</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00583-2</pub-id><pub-id pub-id-type="pmid">34312520</pub-id><pub-id pub-id-type="pmcid">PMC8312369</pub-id></element-citation></ref><ref id="B54-pharmaceutics-15-01850"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sengupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azharuddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Devito</surname><given-names>C.</given-names></name><name name-style="western"><surname>von Castelmur</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wehlin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pietras</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sunnerhagen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seleg&#229;rd</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aili</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>504</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10040504</pub-id><pub-id pub-id-type="pmid">35455253</pub-id><pub-id pub-id-type="pmcid">PMC9029453</pub-id></element-citation></ref><ref id="B55-pharmaceutics-15-01850"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Devnath</surname><given-names>P.</given-names></name><name name-style="western"><surname>Emran</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Tallei</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name></person-group><article-title>Oral and Intranasal Vaccines against SARS-CoV-2: Current Progress, Prospects, Advantages, and Challenges</article-title><source>Immun. Inflamm. Dis.</source><year>2022</year><volume>10</volume><fpage>e604</fpage><pub-id pub-id-type="doi">10.1002/iid3.604</pub-id><pub-id pub-id-type="pmid">35349752</pub-id><pub-id pub-id-type="pmcid">PMC8959423</pub-id></element-citation></ref><ref id="B56-pharmaceutics-15-01850"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Focosi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name></person-group><article-title>Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>187</elocation-id><pub-id pub-id-type="doi">10.3390/v14020187</pub-id><pub-id pub-id-type="pmid">35215783</pub-id><pub-id pub-id-type="pmcid">PMC8878800</pub-id></element-citation></ref><ref id="B57-pharmaceutics-15-01850"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halberg</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Lyby</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wassermann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zijlstra</surname><given-names>E.</given-names></name><name name-style="western"><surname>Plum-M&#246;rschel</surname><given-names>L.</given-names></name></person-group><article-title>Efficacy and Safety of Oral Basal Insulin versus Subcutaneous Insulin Glargine in Type 2 Diabetes: A Randomised, Double-Blind, Phase 2 Trial</article-title><source>Lancet Diabetes Endocrinol.</source><year>2019</year><volume>7</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(18)30372-3</pub-id><pub-id pub-id-type="pmid">30679095</pub-id></element-citation></ref><ref id="B58-pharmaceutics-15-01850"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>Y.H.</given-names></name></person-group><article-title>Multifunctional Oral Delivery Systems for Enhanced Bioavailability of Therapeutic Peptides/Proteins</article-title><source>Acta Pharm. Sin. B</source><year>2019</year><volume>9</volume><fpage>902</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2019.01.004</pub-id><pub-id pub-id-type="pmid">31649842</pub-id><pub-id pub-id-type="pmcid">PMC6804447</pub-id></element-citation></ref><ref id="B59-pharmaceutics-15-01850"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozsoy</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gungor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cevher</surname><given-names>E.</given-names></name></person-group><article-title>Nasal Delivery of High Molecular Weight Drugs</article-title><source>Molecules</source><year>2009</year><volume>14</volume><fpage>3754</fpage><lpage>3779</lpage><pub-id pub-id-type="doi">10.3390/molecules14093754</pub-id><pub-id pub-id-type="pmid">19783956</pub-id><pub-id pub-id-type="pmcid">PMC6254717</pub-id></element-citation></ref><ref id="B60-pharmaceutics-15-01850"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sodha</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagarkar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>H.</given-names></name></person-group><article-title>Translation of Pulmonary Protein Therapy from Bench to Bedside: Addressing the Bioavailability Challenges</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>64</volume><fpage>102664</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102664</pub-id></element-citation></ref><ref id="B61-pharmaceutics-15-01850"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barona</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ordoubadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bin Karim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carrigy</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>McCollum</surname><given-names>J.</given-names></name><name name-style="western"><surname>Press</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Microparticle Encapsulation of a Tuberculosis Subunit Vaccine Candidate Containing a Nanoemulsion Adjuvant via Spray Drying</article-title><source>Eur. J. Pharm. Biopharm. Off. J. Arb. Pharm. Verfahr. EV</source><year>2021</year><volume>163</volume><fpage>23</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2021.03.007</pub-id><pub-id pub-id-type="pmcid">PMC8096719</pub-id><pub-id pub-id-type="pmid">33753213</pub-id></element-citation></ref><ref id="B62-pharmaceutics-15-01850"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Rolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eldam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sivananthan</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kinsey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abhyankar</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Intranasal Delivery of a Synthetic Entamoeba Histolytica Vaccine Containing Adjuvant (LecA + GLA-3 M-052 Liposomes): In Vitro Characterization</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>626</volume><fpage>122141</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122141</pub-id><pub-id pub-id-type="pmid">36058408</pub-id><pub-id pub-id-type="pmcid">PMC11702343</pub-id></element-citation></ref><ref id="B63-pharmaceutics-15-01850"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name></person-group><article-title>Inflammatory Responses and Inflammation-Associated Diseases in Organs</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>7204</fpage><lpage>7218</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23208</pub-id><pub-id pub-id-type="pmid">29467962</pub-id><pub-id pub-id-type="pmcid">PMC5805548</pub-id></element-citation></ref><ref id="B64-pharmaceutics-15-01850"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Linder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spyr</surname><given-names>C.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>R.</given-names></name></person-group><article-title>Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell&#8217;s Palsy in Switzerland</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>896</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030595</pub-id><pub-id pub-id-type="pmid">14985487</pub-id></element-citation></ref><ref id="B65-pharmaceutics-15-01850"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>S.P.</given-names></name></person-group><article-title>Drug Delivery to the Lungs: Challenges and Opportunities</article-title><source>Ther. Deliv.</source><year>2017</year><volume>8</volume><fpage>647</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.4155/tde-2017-0037</pub-id><pub-id pub-id-type="pmid">28730933</pub-id></element-citation></ref><ref id="B66-pharmaceutics-15-01850"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>H.</given-names></name></person-group><article-title>Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>672</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12070672</pub-id><pub-id pub-id-type="pmid">32708881</pub-id><pub-id pub-id-type="pmcid">PMC7408216</pub-id></element-citation></ref><ref id="B67-pharmaceutics-15-01850"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Ramani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lopman</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Church</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Iturriza-G&#243;mara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prendergast</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Grassly</surname><given-names>N.C.</given-names></name></person-group><article-title>Causes of Impaired Oral Vaccine Efficacy in Developing Countries</article-title><source>Future Microbiol.</source><year>2018</year><volume>13</volume><fpage>97</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.2217/fmb-2017-0128</pub-id><pub-id pub-id-type="pmid">29218997</pub-id><pub-id pub-id-type="pmcid">PMC7026772</pub-id></element-citation></ref><ref id="B68-pharmaceutics-15-01850"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Picece</surname><given-names>V.C.T.M.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Designing Spatial and Temporal Control of Vaccine Responses</article-title><source>Nat. Rev. Mater.</source><year>2022</year><volume>7</volume><fpage>174</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00372-2</pub-id><pub-id pub-id-type="pmid">34603749</pub-id><pub-id pub-id-type="pmcid">PMC8477997</pub-id></element-citation></ref><ref id="B69-pharmaceutics-15-01850"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Aung</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.</given-names></name></person-group><article-title>Controlling Timing and Location in Vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>158</volume><fpage>91</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.06.019</pub-id><pub-id pub-id-type="pmid">32598970</pub-id><pub-id pub-id-type="pmcid">PMC7318960</pub-id></element-citation></ref><ref id="B70-pharmaceutics-15-01850"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirelli</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Carnathan</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Nogal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>O.L.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Enemuo</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Gebru</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Viviano</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1153</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.012</pub-id><pub-id pub-id-type="pmid">31080066</pub-id><pub-id pub-id-type="pmcid">PMC6619430</pub-id></element-citation></ref><ref id="B71-pharmaceutics-15-01850"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tam</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pelet</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ruda</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crampton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baldeon</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Sustained Antigen Availability during Germinal Center Initiation Enhances Antibody Responses to Vaccination</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E6639</fpage><lpage>E6648</lpage><pub-id pub-id-type="doi">10.1073/pnas.1606050113</pub-id><pub-id pub-id-type="pmid">27702895</pub-id><pub-id pub-id-type="pmcid">PMC5086995</pub-id></element-citation></ref><ref id="B72-pharmaceutics-15-01850"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Meany</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Grosskopf</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Adamska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Picece</surname><given-names>V.C.T.M.</given-names></name><name name-style="western"><surname>d&#8217;Aquino</surname><given-names>A.I.</given-names></name><etal/></person-group><article-title>Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2</article-title><source>Adv. Mater.</source><year>2021</year><volume>33</volume><fpage>2104362</fpage><pub-id pub-id-type="doi">10.1002/adma.202104362</pub-id><pub-id pub-id-type="pmid">34651342</pub-id><pub-id pub-id-type="pmcid">PMC8646307</pub-id></element-citation></ref><ref id="B73-pharmaceutics-15-01850"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Najibi</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Sharda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scadden</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>D.J.</given-names></name></person-group><article-title>A Biomaterial-Based Vaccine Eliciting Durable Tumour-Specific Responses against Acute Myeloid Leukaemia</article-title><source>Nat. Biomed. Eng.</source><year>2020</year><volume>4</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/s41551-019-0503-3</pub-id><pub-id pub-id-type="pmid">31937942</pub-id></element-citation></ref><ref id="B74-pharmaceutics-15-01850"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirelli</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S.</given-names></name></person-group><article-title>Germinal Center Enhancement by Extended Antigen Availability</article-title><source>Curr. Opin. Immunol.</source><year>2017</year><volume>47</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.06.008</pub-id><pub-id pub-id-type="pmid">28738289</pub-id><pub-id pub-id-type="pmcid">PMC5626612</pub-id></element-citation></ref><ref id="B75-pharmaceutics-15-01850"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bobbala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hook</surname><given-names>S.</given-names></name></person-group><article-title>Vaccine Implants: Current Status and Recent Advancements</article-title><source>Emerg. Top. Life Sci.</source><year>2021</year><volume>4</volume><fpage>601</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1042/ETLS20200164</pub-id><pub-id pub-id-type="pmid">33231265</pub-id></element-citation></ref><ref id="B76-pharmaceutics-15-01850"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mudzingwa</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>I.K.</given-names></name></person-group><article-title>Long-Acting Injections for HIV Prevention among Women in Sub-Saharan Africa</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>1754</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00613-4</pub-id><pub-id pub-id-type="pmid">35378079</pub-id></element-citation></ref><ref id="B77-pharmaceutics-15-01850"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Atujuna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krogstad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ndwayana</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>L.-G.</given-names></name><name name-style="western"><surname>Van Der Straten</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minnis</surname><given-names>A.M.</given-names></name></person-group><article-title>The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-Exposure Prophylaxis to HIV Among South African Youth</article-title><source>JAIDS J. Acquir. Immune Defic. Syndr.</source><year>2019</year><volume>80</volume><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001960</pub-id><pub-id pub-id-type="pmid">30865050</pub-id><pub-id pub-id-type="pmcid">PMC6426447</pub-id></element-citation></ref><ref id="B78-pharmaceutics-15-01850"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saouaf</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.A.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Grosskopf</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Picece</surname><given-names>V.C.T.M.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Modulation of Injectable Hydrogel Properties for Slow Co-delivery of Influenza Subunit Vaccine Components Enhance the Potency of Humoral Immunity</article-title><source>J. Biomed. Mater. Res. A</source><year>2021</year><volume>109</volume><fpage>2173</fpage><lpage>2186</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.37203</pub-id><pub-id pub-id-type="pmid">33955657</pub-id><pub-id pub-id-type="pmcid">PMC8518857</pub-id></element-citation></ref><ref id="B79-pharmaceutics-15-01850"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Alc&#225;ntara-Hern&#225;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Axpe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Lopez Hernandez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maikawa</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Injectable Hydrogels for Sustained Codelivery of Subunit Vaccines Enhance Humoral Immunity</article-title><source>ACS Cent. Sci.</source><year>2020</year><volume>6</volume><fpage>1800</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.0c00732</pub-id><pub-id pub-id-type="pmid">33145416</pub-id><pub-id pub-id-type="pmcid">PMC7596866</pub-id></element-citation></ref><ref id="B80-pharmaceutics-15-01850"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Saouaf</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bruun</surname><given-names>T.U.J.</given-names></name><name name-style="western"><surname>Baillet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>King</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine</article-title><source>Adv. Healthc. Mater.</source><year>2023</year><comment><italic toggle="yes">in press</italic></comment><pub-id pub-id-type="doi">10.1002/adhm.202301495</pub-id><pub-id pub-id-type="pmid">37278391</pub-id></element-citation></ref><ref id="B81-pharmaceutics-15-01850"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marin-Acevedo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kimbrough</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name></person-group><article-title>Next Generation of Immune Checkpoint Inhibitors and Beyond</article-title><source>J. Hematol. Oncol.</source><year>2021</year><volume>14</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01056-8</pub-id><pub-id pub-id-type="pmid">33741032</pub-id><pub-id pub-id-type="pmcid">PMC7977302</pub-id></element-citation></ref><ref id="B82-pharmaceutics-15-01850"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esfahani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roudaia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buhlaiga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Del Rincon</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Papneja</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>W.H.</given-names></name></person-group><article-title>A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future</article-title><source>Curr. Oncol.</source><year>2020</year><volume>27</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.3747/co.27.5223</pub-id><pub-id pub-id-type="pmcid">PMC7194005</pub-id><pub-id pub-id-type="pmid">32368178</pub-id></element-citation></ref><ref id="B83-pharmaceutics-15-01850"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name></person-group><article-title>From Discovery to Licensure, the Adjuvant System Story</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1225635</pub-id><pub-id pub-id-type="pmcid">PMC5287309</pub-id><pub-id pub-id-type="pmid">27636098</pub-id></element-citation></ref><ref id="B84-pharmaceutics-15-01850"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herv&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chalon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Helden</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Genito</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>N.C.</given-names></name><etal/></person-group><article-title>Cellular and Molecular Synergy in AS01-Adjuvanted Vaccines Results in an Early IFN&#947; Response Promoting Vaccine Immunogenicity</article-title><source>Npj Vaccines</source><year>2017</year><volume>2</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0027-3</pub-id><pub-id pub-id-type="pmid">29263880</pub-id><pub-id pub-id-type="pmcid">PMC5627273</pub-id></element-citation></ref><ref id="B85-pharmaceutics-15-01850"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberger</surname><given-names>B.</given-names></name></person-group><article-title>Adjuvant Strategies to Improve Vaccination of the Elderly Population</article-title><source>Curr. Opin. Pharmacol.</source><year>2018</year><volume>41</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2018.03.014</pub-id><pub-id pub-id-type="pmid">29677646</pub-id></element-citation></ref><ref id="B86-pharmaceutics-15-01850"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polhemus</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Remich</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ogutu</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Waitumbi</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Apollo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e6465</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006465</pub-id><pub-id pub-id-type="pmid">19649245</pub-id><pub-id pub-id-type="pmcid">PMC2714466</pub-id></element-citation></ref><ref id="B87-pharmaceutics-15-01850"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorostkar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Arashkia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roohvand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shoja</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Navari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mashhadi Abolghasem Shirazi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahosseini</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Farahmand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shams Nosrati</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Jalilvand</surname><given-names>S.</given-names></name></person-group><article-title>Co-administration of 2&#8242;3&#8242;-CGAMP STING Activator and CpG-C Adjuvants with a Mutated Form of HPV 16 E7 Protein Leads to Tumor Growth Inhibition in the Mouse Model</article-title><source>Infect. Agent. Cancer</source><year>2021</year><volume>16</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s13027-021-00346-7</pub-id><pub-id pub-id-type="pmid">33499895</pub-id><pub-id pub-id-type="pmcid">PMC7836183</pub-id></element-citation></ref><ref id="B88-pharmaceutics-15-01850"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abhyankar</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Kinsey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sivananthan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nafziger</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Oakland</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Young</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Farr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>683157</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.683157</pub-id><pub-id pub-id-type="pmid">34248966</pub-id><pub-id pub-id-type="pmcid">PMC8268010</pub-id></element-citation></ref><ref id="B89-pharmaceutics-15-01850"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lockman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bisteau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kielland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vosters</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vanderheyde</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schiavetti</surname><given-names>F.</given-names></name><etal/></person-group><article-title>AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>6186</fpage><lpage>6197</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901474</pub-id><pub-id pub-id-type="pmid">19864596</pub-id></element-citation></ref><ref id="B90-pharmaceutics-15-01850"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sapkota</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saud</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Al-Fahad</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name></person-group><article-title>Heterologous Prime&#8211;Boost Strategies for COVID-19 Vaccines</article-title><source>J. Travel Med.</source><year>2021</year><volume>29</volume><fpage>taab191</fpage><pub-id pub-id-type="doi">10.1093/jtm/taab191</pub-id><pub-id pub-id-type="pmid">34918097</pub-id><pub-id pub-id-type="pmcid">PMC8754745</pub-id></element-citation></ref><ref id="B91-pharmaceutics-15-01850"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stuart</surname><given-names>A.S.V.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Greenland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Charlton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Immunogenicity, Safety, and Reactogenicity of Heterologous COVID-19 Primary Vaccination Incorporating MRNA, Viral-Vector, and Protein-Adjuvant Vaccines in the UK (Com-COV2): A Single-Blind, Randomised, Phase 2, Non-Inferiority Trial</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>36</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02718-5</pub-id><pub-id pub-id-type="pmid">34883053</pub-id><pub-id pub-id-type="pmcid">PMC8648333</pub-id></element-citation></ref><ref id="B92-pharmaceutics-15-01850"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sellers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jacob-Dolan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lifton</surname><given-names>M.</given-names></name><name name-style="western"><surname>McMahan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sciacca</surname><given-names>M.</given-names></name><name name-style="western"><surname>VanWyk</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>493</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04465-y</pub-id><pub-id pub-id-type="pmid">35102312</pub-id><pub-id pub-id-type="pmcid">PMC8930761</pub-id></element-citation></ref><ref id="B93-pharmaceutics-15-01850"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Neutralizing Antibody Vaccine for Pandemic and Pre-Emergent Coronaviruses</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03594-0</pub-id><pub-id pub-id-type="pmid">33971664</pub-id><pub-id pub-id-type="pmcid">PMC8528238</pub-id></element-citation></ref><ref id="B94-pharmaceutics-15-01850"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><etal/></person-group><article-title>Adjuvanting a Subunit COVID-19 Vaccine to Induce Protective Immunity</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id></element-citation></ref><ref id="B95-pharmaceutics-15-01850"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Voigt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Battisti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beaver</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dinkins</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mody</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zakin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Heterologous SaRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>910136</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.910136</pub-id><pub-id pub-id-type="pmid">35911728</pub-id><pub-id pub-id-type="pmcid">PMC9335885</pub-id></element-citation></ref><ref id="B96-pharmaceutics-15-01850"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rosati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alicea</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e91550</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0091550</pub-id><pub-id pub-id-type="pmid">24626482</pub-id><pub-id pub-id-type="pmcid">PMC3953433</pub-id></element-citation></ref><ref id="B97-pharmaceutics-15-01850"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>Incorporation of Pseudouridine into MRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability</article-title><source>Mol. Ther.</source><year>2008</year><volume>16</volume><fpage>1833</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.200</pub-id><pub-id pub-id-type="pmid">18797453</pub-id><pub-id pub-id-type="pmcid">PMC2775451</pub-id></element-citation></ref><ref id="B98-pharmaceutics-15-01850"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rejman</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Haes</surname><given-names>W.</given-names></name><name name-style="western"><surname>Verrier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Gulck</surname><given-names>E.</given-names></name><name name-style="western"><surname>Naessens</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bogaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grooten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vanham</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of MRNA Vaccines</article-title><source>Mol. Ther.</source><year>2013</year><volume>21</volume><fpage>251</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.202</pub-id><pub-id pub-id-type="pmid">23011030</pub-id><pub-id pub-id-type="pmcid">PMC3538310</pub-id></element-citation></ref><ref id="B99-pharmaceutics-15-01850"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Hoecke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roose</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ballegeer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>De Koker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saelens</surname><given-names>X.</given-names></name><name name-style="western"><surname>Van Lint</surname><given-names>S.</given-names></name></person-group><article-title>The Opposing Effect of Type I IFN on the T Cell Response by Non-Modified MRNA-Lipoplex Vaccines Is Determined by the Route of Administration</article-title><source>Mol. Ther.-Nucleic Acids</source><year>2020</year><volume>22</volume><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2020.09.004</pub-id><pub-id pub-id-type="pmid">33230442</pub-id><pub-id pub-id-type="pmcid">PMC7533292</pub-id></element-citation></ref><ref id="B100-pharmaceutics-15-01850"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>A Vaccine Strategy That Protects against Genital Herpes by Establishing Local Memory T Cells</article-title><source>Nature</source><year>2012</year><volume>491</volume><fpage>463</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1038/nature11522</pub-id><pub-id pub-id-type="pmid">23075848</pub-id><pub-id pub-id-type="pmcid">PMC3499630</pub-id></element-citation></ref><ref id="B101-pharmaceutics-15-01850"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Cardin</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pullum</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.M.</given-names></name></person-group><article-title>Successful Application of Prime and Pull Strategy for a Therapeutic HSV Vaccine</article-title><source>Npj Vaccines</source><year>2019</year><volume>4</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0129-1</pub-id><pub-id pub-id-type="pmid">31396405</pub-id><pub-id pub-id-type="pmcid">PMC6671986</pub-id></element-citation></ref><ref id="B102-pharmaceutics-15-01850"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanathan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lykins</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Hladik</surname><given-names>F.</given-names></name><name name-style="western"><surname>Woodrow</surname><given-names>K.A.</given-names></name></person-group><article-title>Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport</article-title><source>Am. J. Reprod. Immunol.</source><year>2015</year><volume>74</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1111/aji.12409</pub-id><pub-id pub-id-type="pmid">26118309</pub-id><pub-id pub-id-type="pmcid">PMC4599983</pub-id></element-citation></ref><ref id="B103-pharmaceutics-15-01850"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vahed</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Walia</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Fouladi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>V.T.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/ Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107+ CD8+ T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e00535-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.00535-18</pub-id><pub-id pub-id-type="pmid">29899087</pub-id><pub-id pub-id-type="pmcid">PMC6069188</pub-id></element-citation></ref><ref id="B104-pharmaceutics-15-01850"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shamseldin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Read</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chaiwatpongsakorn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mahesh</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology</article-title><source>J. Immunol.</source><year>2023</year><volume>210</volume><fpage>1257</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200297</pub-id><pub-id pub-id-type="pmid">36881867</pub-id><pub-id pub-id-type="pmcid">PMC10121870</pub-id></element-citation></ref><ref id="B105-pharmaceutics-15-01850"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.-A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name></person-group><article-title>A &#8220;Prime and Deploy&#8221; Strategy for Universal Influenza Vaccine Targeting Nucleoprotein Induces Lung-Resident Memory CD8 T Cells</article-title><source>Immune Netw.</source><year>2021</year><volume>21</volume><fpage>e28</fpage><pub-id pub-id-type="doi">10.4110/in.2021.21.e28</pub-id><pub-id pub-id-type="pmid">34522441</pub-id><pub-id pub-id-type="pmcid">PMC8410988</pub-id></element-citation></ref><ref id="B106-pharmaceutics-15-01850"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Aznar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Korman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gracia</surname><given-names>J.L.P.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.</given-names></name></person-group><article-title>Evolving Synergistic Combinations of Targeted Immunotherapies to Combat Cancer</article-title><source>Nat. Rev. Cancer</source><year>2015</year><volume>15</volume><fpage>457</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/nrc3973</pub-id><pub-id pub-id-type="pmid">26205340</pub-id></element-citation></ref><ref id="B107-pharmaceutics-15-01850"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Agnandji</surname><given-names>S.</given-names></name><name name-style="western"><surname>von Glasenapp</surname><given-names>I.</given-names></name><name name-style="western"><surname>Haertle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oyakhiromen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Issifou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lievens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e7611</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007611</pub-id><pub-id pub-id-type="pmid">19859560</pub-id><pub-id pub-id-type="pmcid">PMC2763199</pub-id></element-citation></ref><ref id="B108-pharmaceutics-15-01850"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spring</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reidler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Angov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bergmann-Leitner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Juompan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e5254</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005254</pub-id><pub-id pub-id-type="pmid">19390585</pub-id><pub-id pub-id-type="pmcid">PMC2669163</pub-id></element-citation></ref><ref id="B109-pharmaceutics-15-01850"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rangel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ghahramani</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lioumi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sotheran</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gaiba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Falciani</surname><given-names>F.</given-names></name></person-group><article-title>Modeling T-Cell Activation Using Gene Expression Profiling and State-Space Models</article-title><source>Bioinformatics</source><year>2004</year><volume>20</volume><fpage>1361</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bth093</pub-id><pub-id pub-id-type="pmid">14962938</pub-id></element-citation></ref><ref id="B110-pharmaceutics-15-01850"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eftimie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cantrell</surname><given-names>D.A.</given-names></name></person-group><article-title>Mathematical Models for Immunology: Current State of the Art and Future Research Directions</article-title><source>Bull. Math. Biol.</source><year>2016</year><volume>78</volume><fpage>2091</fpage><lpage>2134</lpage><pub-id pub-id-type="doi">10.1007/s11538-016-0214-9</pub-id><pub-id pub-id-type="pmid">27714570</pub-id><pub-id pub-id-type="pmcid">PMC5069344</pub-id></element-citation></ref><ref id="B111-pharmaceutics-15-01850"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrew</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>C.T.H.</given-names></name><name name-style="western"><surname>Bocharov</surname><given-names>G.A.</given-names></name></person-group><article-title>Rival Approaches to Mathematical Modelling in Immunology</article-title><source>J. Comput. Appl. Math.</source><year>2007</year><volume>205</volume><fpage>669</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.cam.2006.03.035</pub-id></element-citation></ref><ref id="B112-pharmaceutics-15-01850"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grebennikov</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Donets</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>Orlova</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Argilaguet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meyerhans</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bocharov</surname><given-names>G.A.</given-names></name></person-group><article-title>Mathematical Modeling of the Intracellular Regulation of Immune Processes</article-title><source>Mol. Biol.</source><year>2019</year><volume>53</volume><fpage>718</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1134/S002689331905008X</pub-id><pub-id pub-id-type="pmid">31661480</pub-id></element-citation></ref><ref id="B113-pharmaceutics-15-01850"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baguelin</surname><given-names>M.</given-names></name><name name-style="western"><surname>LeF&#232;vre</surname><given-names>J.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>J.-P.</given-names></name></person-group><article-title>How to Deal with Potentially Huge Dimensional State Space: The Meta-Dynamics Approach&#8212;Application to a Model of the Co-Evolution of Bacterio-Phage Populations</article-title><source>J. Comput. Appl. Math.</source><year>2007</year><volume>205</volume><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.cam.2006.03.036</pub-id></element-citation></ref><ref id="B114-pharmaceutics-15-01850"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lienert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lohmueller</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silver</surname><given-names>P.A.</given-names></name></person-group><article-title>Synthetic Biology in Mammalian Cells: Next Generation Research Tools and Therapeutics</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2014</year><volume>15</volume><fpage>95</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nrm3738</pub-id><pub-id pub-id-type="pmid">24434884</pub-id><pub-id pub-id-type="pmcid">PMC4032074</pub-id></element-citation></ref><ref id="B115-pharmaceutics-15-01850"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Tato</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Furman</surname><given-names>D.</given-names></name></person-group><article-title>Systems Immunology: Just Getting Started</article-title><source>Nat. Immunol.</source><year>2017</year><volume>18</volume><fpage>725</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1038/ni.3768</pub-id><pub-id pub-id-type="pmid">28632713</pub-id><pub-id pub-id-type="pmcid">PMC5790187</pub-id></element-citation></ref><ref id="B116-pharmaceutics-15-01850"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bannigan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Aldeghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#228;se</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.</given-names></name></person-group><article-title>Machine Learning Models to Accelerate the Design of Polymeric Long-Acting Injectables</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-35343-w</pub-id><pub-id pub-id-type="pmid">36627280</pub-id><pub-id pub-id-type="pmcid">PMC9832011</pub-id></element-citation></ref><ref id="B117-pharmaceutics-15-01850"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Querec</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Akondy</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Teuwen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pirani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gernert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marzolf</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Systems Biology Approach Predicts Immunogenicity of the Yellow Fever Vaccine in Humans</article-title><source>Nat. Immunol.</source><year>2009</year><volume>10</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/ni.1688</pub-id><pub-id pub-id-type="pmid">19029902</pub-id><pub-id pub-id-type="pmcid">PMC4049462</pub-id></element-citation></ref><ref id="B118-pharmaceutics-15-01850"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>M.K.D.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wimmers</surname><given-names>F.</given-names></name><name name-style="western"><surname>Grigoryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trisal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Systems Vaccinology of the BNT162b2 MRNA Vaccine in Humans</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03791-x</pub-id><pub-id pub-id-type="pmid">34252919</pub-id><pub-id pub-id-type="pmcid">PMC8761119</pub-id></element-citation></ref><ref id="B119-pharmaceutics-15-01850"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakaya</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kazmin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bosinger</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Zak</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Systems Biology of Immunity to MF59-Adjuvanted versus Nonadjuvanted Trivalent Seasonal Influenza Vaccines in Early Childhood</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>1853</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1073/pnas.1519690113</pub-id><pub-id pub-id-type="pmid">26755593</pub-id><pub-id pub-id-type="pmcid">PMC4763735</pub-id></element-citation></ref><ref id="B120-pharmaceutics-15-01850"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>H.I.</given-names></name></person-group><article-title>Systems Vaccinology</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>516</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.006</pub-id><pub-id pub-id-type="pmid">21029962</pub-id><pub-id pub-id-type="pmcid">PMC3001343</pub-id></element-citation></ref><ref id="B121-pharmaceutics-15-01850"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kummar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kinders</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parchment</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Murgo</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mroczkowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pickeral</surname><given-names>O.K.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phase 0 Clinical Trials: Conceptions and Misconceptions</article-title><source>Cancer J.</source><year>2008</year><volume>14</volume><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e318172d6f3</pub-id><pub-id pub-id-type="pmid">18536551</pub-id><pub-id pub-id-type="pmcid">PMC7185299</pub-id></element-citation></ref><ref id="B122-pharmaceutics-15-01850"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Politis</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rekkas</surname><given-names>D.M.</given-names></name></person-group><article-title>Design of Experiments (DoE) in Pharmaceutical Development</article-title><source>Drug Dev. Ind. Pharm.</source><year>2017</year><volume>43</volume><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1080/03639045.2017.1291672</pub-id><pub-id pub-id-type="pmid">28166428</pub-id></element-citation></ref><ref id="B123-pharmaceutics-15-01850"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durakovic</surname><given-names>B.</given-names></name></person-group><article-title>Design of Experiments Application, Concepts, Examples: State of the Art</article-title><source>Period. Eng. Nat. Sci.</source><year>2017</year><volume>5</volume><fpage>421</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.21533/pen.v5i3.145</pub-id></element-citation></ref><ref id="B124-pharmaceutics-15-01850"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poncet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hessler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gautheron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sergent</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rintala</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Seydoux</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.-W.D.</given-names></name><name name-style="western"><surname>Argilla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Preclinical Optimization of an Enterotoxigenic Escherichia Coli Adjuvanted Subunit Vaccine Using Response Surface Design of Experiments</article-title><source>NPJ Vaccines</source><year>2020</year><volume>5</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-00228-w</pub-id><pub-id pub-id-type="pmid">32983577</pub-id><pub-id pub-id-type="pmcid">PMC7486917</pub-id></element-citation></ref><ref id="B125-pharmaceutics-15-01850"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Festing</surname><given-names>M.F.</given-names></name></person-group><article-title>Randomized Block Experimental Designs Can Increase the Power and Reproducibility of Laboratory Animal Experiments</article-title><source>ILAR J.</source><year>2014</year><volume>55</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1093/ilar/ilu045</pub-id><pub-id pub-id-type="pmid">25541548</pub-id></element-citation></ref><ref id="B126-pharmaceutics-15-01850"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ly</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soriano</surname><given-names>S.K.V.</given-names></name><name name-style="western"><surname>Kis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A.K.</given-names></name></person-group><article-title>Optimization of Lipid Nanoparticles for SaRNA Expression and Cellular Activation Using a Design-of-Experiment Approach</article-title><source>Mol. Pharm.</source><year>2022</year><volume>19</volume><fpage>1892</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00032</pub-id><pub-id pub-id-type="pmid">35604765</pub-id><pub-id pub-id-type="pmcid">PMC9176215</pub-id></element-citation></ref><ref id="B127-pharmaceutics-15-01850"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkhu</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Perrie</surname><given-names>Y.</given-names></name></person-group><article-title>Characterization and Optimization of Bilosomes for Oral Vaccine Delivery</article-title><source>J. Drug Target.</source><year>2013</year><volume>21</volume><fpage>291</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.3109/1061186X.2012.747528</pub-id><pub-id pub-id-type="pmid">30952177</pub-id></element-citation></ref><ref id="B128-pharmaceutics-15-01850"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pavlovi&#263;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Doroti&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zadro</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kapusti&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halassy</surname><given-names>B.</given-names></name></person-group><article-title>Robustness Testing of Live Attenuated Rubella Vaccine Potency Assay Using Fractional Factorial Design of Experiments</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>5497</fpage><lpage>5502</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.04.111</pub-id><pub-id pub-id-type="pmid">20472023</pub-id></element-citation></ref><ref id="B129-pharmaceutics-15-01850"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Block</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Szenborn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jackowska</surname><given-names>T.</given-names></name><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dull</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name></person-group><article-title>A Comparative Evaluation of Two Investigational Meningococcal ABCWY Vaccine Formulations: Results of a Phase 2 Randomized, Controlled Trial</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>2500</fpage><lpage>2510</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.001</pub-id><pub-id pub-id-type="pmid">25795256</pub-id></element-citation></ref><ref id="B130-pharmaceutics-15-01850"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramer</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Dubois Cauwelaert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Beebe</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.-W.D.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>Q.M.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fedor</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Vedvick</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Development of a Thermostable Nanoemulsion Adjuvanted Vaccine against Tuberculosis Using a Design-of-Experiments Approach</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>3689</fpage><lpage>3711</lpage><pub-id pub-id-type="doi">10.2147/IJN.S159839</pub-id><pub-id pub-id-type="pmcid">PMC6028350</pub-id><pub-id pub-id-type="pmid">29983563</pub-id></element-citation></ref><ref id="B131-pharmaceutics-15-01850"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Hanon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name></person-group><article-title>Towards an Evidence Based Approach for the Development of Adjuvanted Vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2017</year><volume>47</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.07.010</pub-id><pub-id pub-id-type="pmid">28755542</pub-id></element-citation></ref><ref id="B132-pharmaceutics-15-01850"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng&#8217;uni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chasara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ndhlovu</surname><given-names>Z.M.</given-names></name></person-group><article-title>Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>590780</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.590780</pub-id><pub-id pub-id-type="pmid">33193428</pub-id><pub-id pub-id-type="pmcid">PMC7655734</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-15-01850-f001" orientation="portrait"><label>Figure 1</label><caption><p>Where do novel adjuvant systems come from, and why are they important? Figure was created with <uri>Biorender.com</uri> (accessed on 26 June 2023).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01850-g001.jpg"/></fig><fig position="float" id="pharmaceutics-15-01850-f002" orientation="portrait"><label>Figure 2</label><caption><p>Careful selection of adjuvants streamlines future pandemic responses. Figure was created with <uri>Biorender.com</uri> (accessed on 26 June 2023).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-01850-g002.jpg"/></fig></floats-group></article></pmc-articleset>